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Understanding the control of viral infections is of broad importance. Chronic 
HCV infection causes decreased expression of the iron hormone hepcidin, 
which is regulated by hepatic BMP/SMAD signaling. We found that HCV infection 
and the BMP/SMAD pathway are mutually antagonistic. HCV blunted induction 
of hepcidin expression by BMP6, likely via TNF-mediated downregulation of the 
BMP co-receptor HJV. In HCV-infected patients, disruption of the BMP6/hepcidin 
axis and genetic variation associated with the BMP/SMAD pathway predicted 
outcome of infection, suggesting BMP/SMAD activity influences antiviral 
immunity. Correspondingly, BMP6 regulated a gene repertoire reminiscent of 
Type I IFN signaling, including upregulating IRFs and downregulating an 
inhibitor of IFN signaling, USP18. Moreover, in BMP stimulated cells, SMAD1 
occupied loci across the genome similar to those bound by IRF1 in IFN 
stimulated cells. Functionally, BMP6 enhanced the transcriptional and antiviral 
response to IFN, but BMP6 and related Activin proteins also potently blocked 
HCV replication independently of IFN. Furthermore, BMP6 and Activin A 
suppressed growth of HBV in cell culture, and Activin A inhibited ZIKV 
replication alone and in combination with IFN. The data establish an 
unappreciated important role for the BMPs and Activins in cellular antiviral 
immunity, which acts independently of, and modulates, IFN. 
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Hepcidin controls iron homeostasis and tissue iron distribution1. Iron is a key nutrient 
for many pathogens, and most infections and inflammation increase hepcidin 
expression2, likely as a host attempt to divert iron away from iron-requiring 
microorganisms. However, HCV infection is associated with low hepcidin, which 
predisposes patients to accumulate liver iron3,4. In the liver, signaling by BMPs 
(including BMP6) and Activins via the SMAD transcription factors controls hepcidin 
transcription, and is vital for maintaining iron homeostasis5. Defective BMP/SMAD 
signaling, brought about by deficiencies in expression of BMP6, BMP receptors or the 
BMP6 coreceptor hemojuvelin (HJV), causes iron overload due to hepcidin 
insufficiency6,7. We hypothesized that HCV infection could cause low hepcidin at least 
in part by inhibiting the BMP pathway. Moreover, there is some evidence that other 
viruses besides HCV interfere with BMP signaling in non-hepatocyte cell types, for 
example the antagonism of BMPR2 by HIV-1 and by KSHV8,9. We were also interested 
in whether the BMP pathway could contribute to innate immune defence against viral 
infection. A recent report indirectly suggested that BMP2 may drive a transcriptome 
that included elements reminiscent of virus-induced and interferon-associated 
responses10. However the functional significance of these effects for viral replication 
and antiviral immunity remained unclear. 
 
We investigated whether HCV inhibited hepcidin production via disruption of the 
BMP/SMAD signaling pathway, and then explored the effects of several different BMPs 
and the related Activin proteins on type I IFN signaling, cellular antiviral responses and 
replication of HCV, HBV and ZIKV. 
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Results 
 
The BMP6/hepcidin axis is impaired by HCV and correlates with outcome of 
infection 
BMP6 is produced by the liver in response to accumulation of iron, and induces 
expression of hepcidin (encoded by HAMP) via BMP receptors and the co-receptor 
HJV on hepatocyte cell membranes5. In chronic HCV infection, hepcidin levels are 
relatively low; furthermore, expression of the BMP6 co-receptor HJV is decreased in 
HCV infected Huh7.5 cells11, suggesting that HCV infection may impair HAMP 
induction by BMP6. Testing this hypothesis, we exposed HCV-infected and uninfected 
Huh7.5 cells to a titration of recombinant BMP6 or BMP9 (which does not bind HJV12). 
HCV-infected cells exhibited a blunted induction of HAMP in response to BMP6 (Figure 
1a), but not to BMP9 (Supplementary Figure 1a). One possible mechanism for this 
effect is through induction of TNF; unlike other viruses, HCV infection is not associated 
with a strong multi-cytokine pro-inflammatory response, although TNF levels are 
raised13. TNFA expression increased with multiplicity of infection of HCV as HJV 
expression fell (Supplementary Figure 1b,c); furthermore TNF dose-dependently 
decreased HJV expression in uninfected hepatoma cells and blunted these cells’ 
response to BMP6 (Supplementary Figure 1d,e). Adding neutralizing anti-TNF 
antibody to HCV infected cells rescued the blunting of hepcidin expression in response 
to BMP6 (Supplementary Figure 1f).  
 We next investigated whether the BMP6/hepcidin axis is altered in patients with 
chronic HCV infection. We analyzed mRNA expression in pre-treatment liver biopsies 
of patients chronically infected with HCV genotypes 1 or 3 whose eventual response 
to antiviral therapy with type I IFN and ribavirin was known (sustained virological 
responder [SVR] or non-responder [NR], Supplementary Table 1). Compared to 
control uninfected liver tissue, pre-treatment NRs had lower HAMP, reduced HJV and 
reduced levels of ID1, a canonical BMP target gene (Figure 1b). HAMP, but not ID1, 
can be regulated by IL6 as well as by BMPs; however, the correlation of ID1 and HAMP 
levels in all groups (Figure 1c), supports the impairment of BMP signaling as the 
primary cause of low hepcidin in HCV infected patients. We also measured liver BMP6 
and calculated HAMP/BMP6 and ID1/BMP6 ratios as assessments of BMP6 target 
gene output per BMP6 input. Both of these ratios were significantly reduced in pre-
treatment NRs (Figure 1d, e). These data indicate that HCV impairs liver BMP6 
signaling and reduces levels of HJV expression, such that synthesis of hepcidin in 
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response to BMP6 is suppressed. Moreover, an impaired BMP6/hepcidin axis is 
associated with failure to respond to antiviral treatment. 
Motivated by this data, we conducted a hypothesis-driven re-analysis of a 
published genome-wide association (GWA) study of response to IFN and ribavirin 
therapy in HCV infected patients14, which found polymorphisms in IL28B to be 
associated with different outcome after therapy. The study provided a list of 100 SNPs 
most associated with differential HCV clearance14, and we examined this dataset to 
investigate whether common genetic variants in the BMP pathway also associate with 
different treatment outcomes. The 100 SNPs covered 66 independent GWA intervals 
(see methods) and contained polymorphisms (listed in Figure 1f) linked to EVI-1 and 
SKIL (which regulate BMP/SMAD signaling15,16), ACVR1/ALK2 (a BMP Type I receptor 
required for hepcidin synthesis17), and BMP6 itself, suggesting a potential enrichment 
of BMP pathway components. To determine the significance of this enrichment (see 
methods), we calculated the likelihood of a) BMP pathway genes occurring in one 
million randomly generated sets of 66 GWA intervals, and b) genes from one million 
randomly generated gene-sets of similar size as the BMP pathway (Supplementary 
Table 2) occurring within the defined 66 GWA intervals. In both cases, the probability 
of four genes (i.e. the number found by the previous study 14) arising by chance was 
very low (p=3.89x10e-4 and p<1x10e-6; Figure 1g). This analysis demonstrates that 
BMP/SMAD pathway genes were significantly over-represented within GWA intervals 
that predict differential HCV clearance in response to pegylated IFN and ribavirin, 
showing that the BMP pathway is an important determinant of the antiviral response 
to HCV in humans. 
 
The transcriptome of BMP6 treated hepatoma cells: altered cell-cycle and IFN 
signaling 
To understand the effects of BMP6 in more depth, we exposed Huh7.5 cells to BMP6 
and measured changes in the transcriptome by microarray. The set of 2275 
significantly differentially expressed genes were subjected to pathway analysis, which 
reported a difference in BMP signaling as expected, changes to cell-cycle regulation, 
and that the type I IFN signaling pathway (and STAT signaling) was altered 
(Supplementary Figure 2). Both BMPs and IFN regulate the cell-cycle; IFN causes 
G0/G1 arrest and this cytostatic property has led to its adoption as a therapy for some 
cancers, as well as for viral infection18. Furthermore, permissivity for HCV replication 
in hepatoma cells depends in part on loss of a virally-activated host protein, CREBL1, 
that inhibits the cell-cycle19. Therefore we tested how BMP6 influenced cell-cycle 
progression on Huh7 cells, using the cytostatic agent UCN-01 as a positive control that 
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elicits cell-cycle arrest partly via transcriptional induction of the cyclin-CDK inhibitor 
p21 (encoded by CDKN1A). BMP6 increased HAMP as expected and upregulated 
CDKN1A, and reduced the number of cells in S-phase due to accumulation in G0/G1 
and G2/M (Supplementary Figure 3a,b). UCN-01 had similar effects on cell-cycle 
progression and furthermore inhibited HCV replication in the OR6 HCV replicon line, 
in which luciferase is used as a measure of HCV replication20, to a similar extent to 
IFN (Supplementary Figure 3c).  
Specific genes in the IFN signaling pathway altered by BMP6 in the microarray 
are shown in Supplementary Figure 4. We confirmed by qPCR that IFNAR2, JAK1, 
STAT2, IRF9, IFI6 and ISG15 were increased by BMP6 in Huh7 cells (Figure 1h); 
STAT2, IRF9, IFI6, and ISG15 mRNA were also upregulated in primary human 
hepatocytes exposed to BMP6, although JAK1 and IFNAR2 were not significantly 
upregulated (Supplementary Figure 5). Of the 2275 differentially expressed genes we 
found 62 members of the 355 ‘interferon stimulated gene’ (ISG) set investigated 
previously for their anti-HCV properties21; the identity of these genes, the direction of 
regulation by BMP6 and their known effects on HCV replication are shown in 
Supplementary Table 3. 
 
Genome-wide loci bound by SMAD1 include multiple antiviral loci and 
substantially overlap with loci bound by IRF1 
To further understand how BMP signaling might interact with the IFN pathway, we 
focused on the genes targeted by SMAD1, which mediates transcriptional effects of 
BMPs in complex with SMAD4. We assessed the specific loci bound by SMAD1 by 
interrogating genome-wide ChIPseq datasets of BMP4-treated erythroleukemic K562 
cells and monocytic U937 cells (Supplementary Table 4). We assigned SMAD1 
associated peaks with their putative cis-regulated target gene loci. In both cell types, 
pathway analysis of genomic loci bound by SMAD1 indicated changes to TGFbeta-
type signaling and SMAD signaling as expected, and alteration of the Type I IFN 
response (Supplementary Figure 6), consistent with the pathway analysis of our 
microarray data from BMP6-treated Huh7 cells (Supplementary Figure 2). BMP4 
treatment of K562 and U937 cells caused SMAD1 to bind to loci of multiple genes 
associated with the Type I IFN response (genes and exact binding loci are specified in 
Supplementary Tables 5, 6) including IFNAR2, JAK1 and STAT2, the mRNA 
expression of which were upregulated in hepatoma cells by BMP6 (Fig. 1h). 
For K562 cells, further available ChIPseq datasets22,23 allowed genome-wide 
comparison of SMAD1 bound loci to the loci bound by other transcription factors, and 
we developed and validated an approach to analyze this (see Supplemental Methods). 
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Figure 2a visualizes the overlap of loci bound by SMAD1 after BMP4 treatment with 
loci bound by IRF1, STAT1 and STAT2 after IFN treatment, and shows considerable 
loci in common between SMAD1 and IRF1. RNA Polymerase II was present at many 
of the loci shared between SMAD1 and IRF1, indicating the genes are actively 
expressed (Figure 2b). Mapping the specific transcription factor binding peaks, SMAD1 
binding in BMP4-treated K562 cells was enriched +/- 500bp around the loci bound by 
IRF1 (a key mediator of broad antiviral activity21) in IFN treated K562 cells (Figure 2c). 
This enrichment of SMAD1 binding in the region of IRF1 binding was not apparent in 
K562 cells treated with dorsomorphin, a small molecule BMP type I receptor kinase 
antagonist that prevents SMAD1 activation24 (Figure 2c), showing that stimulation of 
the BMP signaling pathway is required for the IRF1-like occupancy of loci by SMAD1. 
Binding of other transcription factors that lack roles in antiviral immunity was not 
enriched proximal to IRF1-bound loci (Figure 2d). However, and as a further control, 
genome-wide binding of STAT1 and STAT2 (which are involved in antiviral immune 
responses) did show some overlap with IRF1 binding in IFNalpha treated cells (Figure 
2e), to a similar degree to that of SMAD1 in BMP4 treated cells. This ChIPseq analysis 
shows that, genome-wide, there was overlap between those loci occupied by IRF1 
after IFN/JAK/STAT signaling and those loci occupied by the transcription factor 
SMAD1 after BMP/SMAD signaling. Electromobility-shift assays showed that IRF1 
binds interferon-sensitive response elements (ISRE) but not BMP response elements 
(BRE), while SMAD4 binds BRE but not ISRE (Supplementary Figure 7). Therefore it 
is unlikely that ISG-type antiviral genes are upregulated by BMP6 due to SMADs and 
IRFs being able to separately target each other’s consensus binding site.  
 
BMP6 regulates expression of several key antiviral effectors 
We noted that several IRF loci were also bound by SMAD1 in BMP4-treated cells, 
including IRF1 itself, IRF2 and IRF7, all individually implicated as critical components 
of broadly acting antiviral immunity that can suppress viral replication (including HCV 
replication)21. We found that IRF1, IRF2 and IRF7 mRNA expression was significantly 
upregulated by BMP6 in hepatoma cells (Figure 3a, Supplementary Figure 8a). IRF1, 
IRF2 and IRF7 can also be regulated by IFN, so we sought to confirm that BMP6 and 
IFN act via different signalling pathways. IFN but not BMP6 strongly induced STAT1 
phosphorylation while BMP6 caused dose-dependent SMAD1/5/8 phosphorylation, 
which was inhibited by the dorsomorphin-like BMP type I receptor kinase antagonist 
LDN-19318924; IFN appeared to cause a very small degree of SMAD1/5/8 
phosphorylation, but at a much lower level compared to the lowest dose of BMP6 
(2nM), and this effect of IFN was not apparently dose-dependent (Figure 3b). 
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Furthermore we found that LDN-193189 and dorsomorphin blocked the upregulation 
of IRF1 by BMP6 but not by IFN (Figure 3c). A similar effect was observed for IRF2, 
and upregulation of IRF7 by BMP6 was also inhibited by LDN-193189 and 
dorsomorphin, while IFN did not upregulate IRF7 mRNA (Supplementary Figure 8a).  
We also noted SMAD1 binding at the loci of USP18, an HCV restriction factor 
and critical negative feedback inhibitor of IFN25,26. BMP6 stimulation downregulated 
USP18 expression (i.e. the opposite effect of IFN stimulation); this downregulation of 
USP18 was rescued by LDN-193189 but not by the JAK kinase inhibitor ruxolitinib27 
(Figure 3d). In contrast, the upregulation of USP18 by IFN was blocked by ruxolitinib 
but not by LDN-193189 (Figure 3d).  
Together these data show that BMP6 regulates mRNA expression of key 
components of the antiviral signaling apparatus independently of IFN, and in the case 
of the IFN signaling inhibitor USP18, the direction of regulation by BMP6 is opposite 
to that of IFN, potentially favouring antiviral activity by derepressing the IFN pathway. 
 
BMP6 enhances STAT phosphorylation and transcriptional and antiviral 
response to IFN 
Because BMP6 upregulated IFNAR2 and components of the intracellular signal 
transduction machinery (JAK1, STAT2, IRF1, IRF2, IRF7, IRF9), and downregulated 
USP18 (which inhibits JAK1 binding to IFNAR225), we hypothesized BMP6 might 
enhance the cellular response to IFN, and we tested this in three ways. First we found 
that STAT1 phosphorylation following IFN exposure was significantly increased if cells 
had been pre-treated with BMP6 (Figure 4a), consistent with previously described 
effects of USP18 deficiency28. Second, we assayed the effect of BMP6 on the IFN-
mediated increase in mRNA of seven interferon-stimulated genes (ISGs): MX1, IFI6, 
ISG15, IFIT3, IFITM1, PLSCR1, TRIM14 – the latter four of which are required for 
suppression of HCV by IFN29. BMP6 pre-treatment significantly increased response to 
IFN for all these ISGs (Figure 4b, Supplementary Figure 8b). We also found that BMP6 
enhances the protein levels of MDA5/IFIH1, which regulates sensing and control of 
HCV infection30, in response to a titration of IFN (Figure 4c). Third, we tested whether 
BMP6 could enhance the antiviral effects of IFN on HCV. We found that BMP6 
increased the anti-HCV activity of both IFNalpha and IFNlambda3 (encoded by IL28B, 
polymorphisms in which are associated with differential HCV clearance14) in the OR6 
HCV replicon cell culture system20 (Figure 4d, e). BMP6 also increased the ability of 
IFNalpha to restrict the growth of replication competent JFH1 HCV in Huh7.5 cells, as 
assessed by staining for HCV core protein (Figure 4f). These results show that BMP6 
enhances IFN activity.  
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Multiple BMPs and Activins are directly antiviral against HCV 
SMAD1 and IRF1 binding peaks were observed in close proximity in active 
regulatory chromatin regions in K562 cells and primary CD34+ cells near directly 
antiviral effector genes RSAD2 (viperin), SSBP3, ZC3HAV1 (ZAP) (Supplementary 
Figure 9a-c), suggesting expression of these genes may be influenced by BMPs, and 
indeed BMP6 increased mRNA expression of RSAD2, SSBP3, ZC3HAV1 in Huh7 
cells (Supplementary Figure 9d). We then considered that BMPs might have IFN-
independent antiviral effects because BMP6 modulated key antiviral immune response 
regulators (IRF1, IRF2, IRF7), and increased expression of directly acting antiviral 
effector genes (RSAD2, SSBP3, ZC3HAV1). Furthermore, we noted that as well as 
boosting the antiviral effects of IFN, BMP6 also appeared to impair viral replication in 
the absence of added IFN in Figure 4f. Testing this idea further, adding BMP6 to 
cultures immediately after infecting Huh7.5 cells with JFH1 HCV restricted the 
accumulation of HCV RNA in culture supernatants (Figure 5a). After day 5 of culture, 
we found increased cellular expression of BMP target genes HAMP, ID1 and SMAD7 
as a function of increasing BMP6 concentration, a general trend towards upregulation 
of IFNAR2, JAK1, STAT2, IRF1 and IRF9 expression, and a significant downregulation 
of USP18 (Supplementary figure 10a-c), observations consistent with our previous 
data above (Fig 1h, 3). The addition of BMP6 to cultures in which HCV had already 
been replicating for 3 days significantly reduced cellular and supernatant HCV RNA 
measured after a further 7 days (Figure 5b); and BMP6 added in the absence of IFN 
suppressed activity of the OR6 HCV replicon over time (Figure 5c). Suppression of 
HCV replication by BMP6 was prevented by LDN-193189 and dorsomorphin (Figure 
5d), but not by ruxolitinib or anti-IFNAR2 antibodies (Figure 5e). Conversely, anti-
IFNAR2 and ruxolitinib, but neither LDN-193189 nor dorsomorphin, prevented 
suppression of HCV replication by IFN (Figure 5e, Supplementary Figure 11a). 
Antiviral transcriptional responses are regulated by the phosphorylation of IRF3 and 
IRF7 by kinases TBK1 / IKKepsilon, which can be inhibited by the small molecule 
Bx79531. We found that Bx795 reduced the antiviral effects of both BMP6 and IFN in a 
dose-dependent fashion so that at 1uM Bx795 neither BMP6 nor IFN significantly 
suppressed replicon growth (Supplementary figure 11b). Therefore, the antiviral 
activity of BMP6, but not that of IFN, requires BMP-SMAD signaling, whereas IFN but 
not BMP6 requires IFNAR2 and JAK-STAT signaling; however, the antiviral activity of 
both BMP6 and IFN appear to require directly or indirectlyTBK1 / IKKepsilon kinase 
activity. 
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 A previous report suggested BMP7 may have anti-HCV activity32; we also 
found that BMP9 and BMP4 (which like BMP6 and BMP7 bind the BMP type I 
receptors), suppressed HCV replication, whereas BMP15, GDF15, and GDF1, which 
bind other receptors, had no such activity (Supplementary Figure 11c, d). We next 
tested the effects of Activin B, a non-BMP TGF-beta superfamily member that can bind 
HJV and BMP type I receptors, and causes SMAD1/5/8 phosphorylation and induces 
hepcidin in liver-derived cells33. Activin B suppressed HCV replication (Figure 5f) in a 
manner partially blocked by LDN-193189 (Supplementary Figure 11e), and we found 
similar results for Activin A (Figure 5f, Supplementary Figure 11e), which also can 
induce hepcidin transcription, although not as potently as Activin B34. 
 
Antiviral activity of BMP6 and Activin A against HBV and ZIKV 
BMP signaling controls expression of genes that regulate a broadly acting 
antiviral response, so we considered whether BMPs (and Activins) may have activity 
against other viruses besides HCV. Furthermore, inhibition of USP18 and upregulation 
of RSAD2 and ZC3HAV1 (which we showed above are caused by BMP6) have each 
been independently associated with control of the double stranded DNA virus, 
Hepatitis B virus (HBV)35-37. Therefore, we tested the ability of BMP6, and Activin A, to 
inhibit growth of HBV. In HepaRG cells harboring replicating HBV, we found that BMP6 
reduced the production of HBV S protein (HBsAg) from infected cells in a dose 
dependent manner, and HBsAg levels were also potently suppressed by Activin A to 
a degree similar to that caused by IFNalpha or the anti-HBV drug lamivudine (Figure 
6a). Finally, we assessed the effects of Activin A on Zika virus (ZIKV) replication in the 
lung epithelial cell line A549. Akin to HCV, ZIKV is a positive sense ssRNA virus of the 
Flaviviridae family. We found that IFNalpha and Activin A individually inhibited viral 
replication (Figure 6b,c) and that Activin A and IFN together had an increased antiviral 
effect compared to IFN alone (Figure 6d, e). 
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Discussion 
Previously the relationship between HCV replication, iron and hepcidin has been 
explored with conflicting results38-41. We propose that low hepcidin and the consequent 
mild liver iron accumulation observed in chronic HCV infection does not strongly 
influence HCV replication directly, but instead is a consequence of the disruption of 
BMP/SMAD signaling by HCV. Mechanistically we found that TNF expression is 
induced by HCV infection, inhibits expression of the BMP6 co-receptor HJV, and is 
required for HCV-mediated suppression of hepcidin induction by BMP6. A recent study 
showed that TNF increases expression of the IFN signaling inhibitor protein, USP18, 
in hepatoma cells42. Therefore, TNF, induced in hepatocytes by HCV and acting intra-
hepatically, appears to inhibit both BMP and IFN signaling.  
 Conversely, we found that BMPs (and the related proteins Activin A and B) 
suppress HCV replication. This reciprocal interaction of HCV and BMP/SMAD is 
reminiscent of that between HCV (and many other viruses) and IFN (see scheme in 
Supplementary figure 12). Moreover, we found that both BMP6 and Activin A restrict 
replication of the DNA virus HBV and that Activin A inhibits ZIKV replication. A separate 
study showed that BMP2 reduces the replication of another DNA virus MHV68 
gammaherpes virus (through undetermined mechanisms)43. Future studies should 
address which viruses are sensitive to BMPs/Activins, possibly in conjunction with IFN, 
and whether antagonism of the BMP and/or Activin pathways is a frequent feature of 
viral infection. 
The mechanisms behind the IFN-independent antiviral activity and the IFN-
enhancing properties of BMP/SMAD signaling are likely due to the regulation of a 
complex gene repertoire that contains many components of classical antiviral innate 
immune orchestrators (including IRF1, IRF2, IRF7, IRF9, which in turn regulate many 
other antiviral genes), cell-cycle regulators, and directly acting antiviral genes such as 
RSAD2, SSBP3 and ZC3HAV1. IRF1 is a transcriptional regulator that when 
overexpressed is strongly and broadly antiviral against HCV, yellow fever virus, 
chikungunya virus, Venezuelan equine encephalitis virus and HIV-121; IRF1 also has 
antiviral activity independently of IRF3, IRF5 and IRF744. Overexpression of IRF2 or 
IRF7 is also antiviral against HCV21. USP18 is an inhibitor of IFN signaling25,26 that is 
upregulated in chronic HCV infection, and lower levels of USP18 are associated with 
suppression of viral replication in vitro and a beneficial response to IFN in patients45,46. 
We showed that BMP6 induces expression of IRF1, IRF2 and IRF7, but decreases 
expression of USP18 (via a currently unknown mechanism) in a BMP receptor kinase-
dependent fashion. Similarly, the restriction of HCV replication by BMP6 was 
prevented by BMP pathway inhibitors but not by anti-IFNAR blockade or ruxolitinib-
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mediated JAK-STAT inhibition. This data shows that BMP6 modulates key antiviral 
orchestrators and has anti-HCV activity independently of IFN; but can also potentiate 
IFN, perhaps in part via USP18 downregulation. 
 At a genomewide level we showed that after BMP4 stimulation, SMAD1 was 
located near many genes with well-described roles in the IFN response pathway and 
antiviral immunity (including IRF1, IRF2, IRF7 and USP18). Furthermore, across the 
genome, there was a marked overlap between those loci occupied by IRF1 after IFN 
stimulation and those loci occupied by SMAD1 after BMP4 stimulation. This supports 
the concept that BMP/SMAD signaling is antiviral in a manner reminiscent of IFN/IRF1 
activity, although independently of IFN. Interestingly, SMADs and many IRFs (although 
not IRF1) demonstrate strong electrostatic and topological similarity in their C-terminal 
domains, may derive from a common ancestor47, and can directly interact via 
oligomerisation48. Therefore the antiviral activity of BMP signaling may conceivably 
further interact with IFN function and antiviral immunity through SMAD/IRF 
heterodimerisation. This could explain why Bx795, an inhibitor of TBK1 / IKKepsilon 
that phosphorylates IRF3 and IRF7, counteracted the antiviral effects of both IFN and 
BMP6; future work should explore how the responses induced by BMP6 and IFN 
interconnect at the level of transcription factor activation and binding. 
In summary BMP/SMAD signaling regulates the expression of a broad 
repertoire of antiviral genes, enhances the response to IFN, has antiviral activity 
independent of IFN, and is inhibited by HCV leading to decreased hepcidin. 
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Online methods 
 
Patient biopsy samples 
We investigated 26 HCV patients who had presented at Mater Misericordiae University 
Hospital, Dublin, Ireland or S. Bortolo Hospital, Vicenza, Italy (Supplementary Table 1). Liver 
biopsies were collected prior to the commencement of antiviral therapy using an 18-gauge 
needle and the sample split into two for both histological grading and gene expression analysis. 
Informed written consent was obtained from all patients and the study was approved by the 
Research Ethics Committees of the Mater Misericordiae University Hospital, Dublin and S. 
Bortolo Hospital, Vicenza, Italy. All HCV patients were negative for HBV and HIV-1, and did not 
show clinical evidence of hemochromatosis (transferrin saturation <45%), although serum 
ferritin levels were high-normal (mean 350ug/ml). Patients were classified as sustained 
virological responders (SVRs) if they were found to be HCV RNA negative 6 months after 
treatment finished, or non-responders (NRs) if they remained HCV RNA positive at that time 
point. Treatment consisted of weekly Peg-IFN plus a daily dose of Ribavirin according to body 
weight. The mRNA from liver biopsies was extracted using RNeasy kits (Qiagen) and reverse 
transcribed using the High Capacity RNA-to-cDNA kit (Applied Biosystems). RNA was 
extracted with the inclusion of a gDNA elimination step from a subset of the biopsies (n=17) 
used to determine ID1 mRNA levels. Gene expression was assessed using qRT-PCR as 
described below. Control liver biopsy mRNA samples were obtained from 3h Biomedical 
(Sweden) (all Caucasians, non-alcoholic, negative for viral hepatitis and haemochromatosis) 
and analysed alongside the HCV biopsy samples. 
Cell culture and reagents 
For all cell lines, periodic routine testing for mycoplasma was performed, and experiments 
presented were on mycoplasma negative cells. The hepatoma cell line Hep3B (ATCC) was 
maintained in MEM-alpha supplemented with 10% foetal calf serum (PAA), 2mM glutamine, 
100U/mL penicillin, 0.1mg/mL streptomycin (all Sigma). HuH7 (ATCC) and HuH7.5 (Apath) 
cells were cultured in DMEM supplemented as above. OR6 cells12, and their IFN-cured 
counterpart were cultured in DMEM supplemented as above, but in the case of OR6 cells were 
also supplemented with G418 at 500ug/mL (Sigma). 
Primary human hepatocytes (Pfizer) were plated in 24-well collagen I-coated plates (350 000 
cells per well) in William's E media (Life Technologies) supplemented with 5% foetal calf serum 
and the Primary Hepatocyte Thawing and Plating Supplements kit (Life Technologies), and 
incubated at 37 oC and 5% CO2. After 4 hours, media was changed and supplemented with 50 
ng/ml of recombinant human BMP6 (R&D systems) or PBS. After 18h of incubation, RNA was 
extracted using the RNeasy mini kit (Qiagen), and cDNA was synthesized using the High-
Capacity RNA-to-cDNA™ Kit (Applied Biosystems). Gene expression was analyzed by qRT-
PCR using Taqman probes for each gene and using GAPDH as endogenous control. 
BMP4, 6, 9, 15, GDF1, GDF15, Activin B, TNF-alpha, IFN-lambda and Mouse isotype control 
IgG2A antibody (Clone 20102) were from R&D Systems, IFN-alpha and anti-IFNAR2 antibody 
(Clone MMHAR-2) from PBL Biomedical Laboratories and Hepcidin from Peptide Institute were 
stored and reconstituted as recommended. Dorsomorphin from Tocris Bioscience and LDN-
193189 from Axon Medchem were reconstituted in water, Ruxolitinib from Selleck Chemicals 
was reconstituted in DMSO. All were used at doses described in figure legends. 
Quantitative real-time PCR (qRT-PCR) 
RNA extraction and cDNA synthesis were carried out by using either RNeasy or RNeasy PLUS 
kits with QIAshredder homogenization (all from Qiagen) and the High capacity RNA-to-cDNA 
kit (Applied Biosystems), all according to the manufacturers’ protocols. qRT-PCR reactions 
were performed on an Applied Biosystems 7500 Fast Real-Time PCR System (Applied 
Biosystems). Gene expression was assessed using inventoried Taqman Gene Expression 
Assays with Taqman Gene Expression Master Mix (both Applied Biosystems) following the 
manufacturer’s instructions. Samples were run in duplicate and gene expression levels were 
quantified relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression 
using the delta Ct method, except for HCV RNA quantification (method detailed below); in some 
cases relative expression was then evaluated further by normalizing to the untreated controls 
(delta-delta Ct method). 
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Flow Cytometry 
HuH7.5 cells treated with or without BMP6 for 18-20 hours followed by a titration of IFN-alpha 
doses (100-10,000U/mL) were fixed at 30 mins post-IFN-alpha addition using BD Cytofix for 10 
minutes followed by permeablisation using BD Perm Buffer III (both BD Biosciences) according 
to the manufacturer’s protocols. Cells were then stained using an anti-pSTAT1(pY701)-
AlexaFluor647 antibody (Clone 4a; BD Biosciences) and an anti-pSTAT3(pY705)-PE antibody 
(Clone 4/P-STAT3; BD Biosciences) or isotype controls: IgG2A-AlexaFluor647 antibody (Clone 
eBM2a; eBioscience) and IgG2A-PE antibody (Clone MOPC-173; BD Biosciences). Cells were 
analysed using a CyAn (Dako).  
Western blotting 
HuH7 cells, seeded at 5x10e4 cells/well (in 500µl, 24-well plate) or 1 x 10e5 cells/well (1mL, 
12-well plate) were treated with or without BMP6, IFN-alpha, or LDN193189 at doses and 
incubation times as described in figure legends. At the end of incubations, cells were washed 
with cold PBS and lysed within the well on ice with cold Pierce RIPA buffer (Thermo Scientific) 
with Protease/Phosphatase Inhibitors (1:100, Cell Signaling Technology). Protein 
concentrations of lysates were quantified using the Pierce BCA Protein Assay kit (Thermo 
Scientific. After incubating with Laemmli Sample buffer (Bio-Rad) with 2-mercaptoethanol (1 in 
10) for 5-20’ at 95ºC, normalised concentrations of protein were separated by 10% SDS-
polyacrylamide gel electrophoresis using Bio-Rad MINI Protean precast gels (Bio-Rad); 
proteins were transferred to nitrocellulose membrane and probed with antibodies against 
phospho-SMAD1/5/8 (Cell Signaling, D5B10), SMAD1 (Cell Signaling, D59D7), phospho-
STAT1(pY701) (Cell Signaling, D4A7), STAT1 (Cell Signaling, 42H3), MDA5 (IFIH1) (Clone 17, 
as described in Hertzog et al13), GAPDH (Proteintech, 60004-1-Ig), or Actin-HRP (AC-15, 
#A3854), and where required HRP-conjugated species-specific secondary antibodies; proteins 
were detected by chemiluminescence with Western Lightning Plus-ECL (Perkin Elmer). 
SNP analysis and BMP pathway enrichment tests 
To investigate the significance of BMP-pathway genes associated with GWA intervals, we 
determined 66 independent GWA-defined intervals from the top 100 SNPs associated with 
differential clearance of HCV in response to antiviral therapy11, derived by: (i) taking the most 
distant pair of SNPs in linkage disequilibrium (r2 > 0.5) with the lead SNP among the haplotypes 
of the 1000 Genomes Project Caucasian individuals 
(http://faculty.washington.edu/browning/beagle/beagle.html), (ii) enlarging the region by 250 kb 
on either side to reflect elements acting at a distance (iii) and by merging any overlapping 
intervals. In each of two complementary approaches to determining gene set enrichment, we 
tested for an enrichment in term of BMP pathway genes 1) Randomising the gene set of 
interest: We compared the number of BMP pathway genes that lay within GWA intervals to 
10e6 randomly generated gene-sets matched in both gene number and gene size (random 
gene-sets approach). (2) Randomising the genomic intervals: We compared the number of 
BMP pathway genes falling in GWA intervals to the number found after randomly shifting of 
GWA intervals 10e6 times while holding for the number of interval-overlapped genes (shifting-
GWA intervals approach). The two approaches are complementary and account for potential 
confounds such linkage disequilibrium structure or localised functional clustering. 
 
Code availability 
The code used to analyse the GWAS data (for figure 1g) is available here: 
http://wwwfgu.anat.ox.ac.uk/downloads/compbio_projects/CW001_SANDOR_BMP/ 
 
Analysis of ChIPseq data 
Previously described ChIP-seq datasets were obtained as FASTQ files from the NCBI GEO 
repository (Series 29196 and Series 31477)14,15. Adaptor sequences were removed using 
TrimGalore (Babraham Institute, University of Cambridge). Reads were aligned to the human 
genome build GRCh37 (UCSC hg19/Feb 2009) with Bowtie2 (v2.2.6)16. Transcription factor 
binding profiles were converted to BedGraph files and visualized in the UCSC genome browser 
accompanied by epigenetic modification tracks defined by the ENCODE project14,17.  
 
For GSE analysis (Supplementary Figure 6), transcription factor binding peaks were identified 
using the findPeaks program in the HOMER suite of NGS analysis tools 
(http://homer.ucsd.edu/homer/ngs/), in accordance with the default parameters and normalized 
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to 10 million total reads per dataset18. Transcription factor-bound loci were associated with their 
putative cis-regulated target genes using GREAT (v2.02), an online tool permitting both 
genome annotation and GSE analysis with reference to multiple ontology databases organized 
by phenotype, disease and regulatory motifs19. GREAT calculates the statistical significance of 
each ontological category within the transcription factor-bound loci with respect to the whole 
genome. Only ontological categories comprising 10-150 terms inclusive were included in final 
analyses, to exclude broad, generic pathways and small gene sets liable to be enriched as 
artefacts of the sampling process. 
 
Venn diagrams (Figure 2a,b) were constructed with the VennDiagram [Hanbo Chen (2015). 
VennDiagram: Generate High-Resolution Venn and Euler Plots. R package version 1.6.16. 
https://CRAN.R-project.org/package=VennDiagram] package in R version 3.2.3 (2015-10-12) 
[R Development Core Team (2008). R: A language and environment for statistical computing. 
R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL 
http://www.R-project.org.]. The annotation of multiple peaks to a single gene within each peak 
set was disregarded for the purpose of this comparison: each unique gene is enumerated in 
each group once, irrespective of the number of distinct ChIP-seq peaks with which it may be 
associated. For comparison of transcription factor binding profiles relative to loci enriched for 
IRF1 binding in IFNalpha-treated K562 (figures 2c-e), transcription factor peaks were called 
with the HOMER findPeaks tool, with each peak defined by 10-fold greater read alignment in 
the target experiment versus input control and all datasets normalized to 10 million total reads. 
Histograms of transcription factor-binding density were constructed using the annotatePeaks.pl 
function in HOMER18. The analysis procedure is divided into three stages. Firstly, one of the 
peak-sets is selected to act as the ‘reference peak-set’. Second, the alignment positions of 
reads from a second ‘comparator’ dataset are compared to the centres of the peaks in the 
reference peak-set. Third, the average densities of the reads in the comparator dataset that 
align +/- 500 bp about the centre of the reference peaks are binned into 50 bp intervals. Finally, 
these data are represented as histograms, with ‘ChIP fragment depth’, an index of read density, 
plotted against their position relative to the centres of the reference peaks. 
 
To test this approach, we compared genome-wide binding of RNA Pol II and RNA Pol III in 
unstimulated K562 cells against the BMP4-SMAD1 and IFNa-IRF1 peak-sets. RNA Pol II is 
required for transcription of mRNA precursors, miRNA and snoRNA, whereas RNA Pol III 
synthesizes 5S RNA, tRNA and various small RNAs including spliceosome components and 
ribozyme. Accordingly, we hypothesized that RNA Pol II binding would be enriched proximal to 
the peak centres across all of the peak sets, being a necessary constituent of the transcriptional 
machinery. In contrast, RNA Pol III targets are minimally IFN or BMP-inducible, to the best of 
our knowledge. As such, we would not anticipate evidence of RNA Pol III binding around the 
centres of the peaks from all of our datasets. The figure below shows that as expected, while 
RNA Pol II binding in unstimulated K562 cells mirrors that of both SMAD1 in BMP4-treated cells 
(i) and IRF1 after IFNα stimulation (ii), enrichment for RNA Pol III binding is undetectable near 
the centre of both BMP4-SMAD1 and IFN-IRF1 peak-sets. Therefore, we then went on to use 
this approach to interrogate the frequency with which a ‘comparator’ transcription factor binds 
in the vicinity of a ‘reference’ transcription factor across the whole genome (see main text and 
Figure 2c-e). 
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Electromobility shift assays 
Electrophoretic mobility shift assays (EMSAs) were carried out in 10 μL reactions whereby 500 
nM IRF1 (NBC-18471, Bio-Techne) or SMAD4 (ab81764, Abcam) was serially diluted two-fold 
and incubated with 0.5 nM of the indicated 25 base pair DNA probe at 37oC for ten minutes. 
Reaction conditions contained 20 mM HEPES, pH 7.5, 50 mM KCl, 0.5 mM DTT, 0.05% Triton-
X, 0.1 mg/mL BSA, 5% glycerol, 50 mM L-arginine-hydrochloride; and 0.01 μg poly(dI:dC) was 
added for reactions with SMAD4. DNA binding was analysed by 6% (for SMAD4) or 8% (for 
IRF1) native PAGE in 0.5 x TBE at 100 V for 3 hours, at 4oC. Gels were dried under vacuum 
for 2 hours at 80oC before being exposed to a Kodak phosphorimager screen and scanned 
using a Typhoon 9400 instrument (GE). 
For 5'[32P] radiolabelling of DNA probes, 10 pmol of single-stranded DNA (Eurofins MWG 
Operon, Germany) was incubated with 6.8 pmoles γ-32P-dATP (Perkin Elmer), and 10 U T4 
PNK (ThermoFisher Scientific) at 37oC for 1 hour. This solution was passed through a P6 Micro 
Bio- Spin chromatography column (BioRad), and the radiolabelled DNA was annealed with the 
appropriate unlabelled oligonucleotide (see below for probe sequences) in a 1:2 molar ratio by 
heating to 95oC and cooling to room temperature in annealing buffer  (10 mM Tris-HCl; pH 7.5, 
100 mM NaCl, 0.1 mM EDTA). 
Probes: Consensus BRE was from the HAMP promoter20: 
HAMP-BRE-25-F: 5’ TCTCCCGCCTTTTCGGCGCCACCAC 
HAMP-BRE-25-R: 5’ GTGGTGGCGCCGAAAAGGCGGGAGA 
Consensus ISRE was from the IFI6 promoter21,22: 
IFI6-ISRE-25-F: 5’ GAGAGGGGAAAATGAAACTGCAGAG 
IFI6-ISRE-25-R: 5’ CTCTGCAGTTTCATTTTCCCCTCTC 
Hepatitis C viral infection 
The Jc1 HCV strain was produced as described previously23. Briefly, HuH7.5 cells were 
transfected with Jc1 RNA by electroporation and supernatants harvested 14-20 days post 
transfection. HuH7.5 cells were infected at a multiplicity of infection (MOI) of 0.02 unless 
otherwise stated. Infection was allowed to proceed for 9-11 days at which point infection was 
greater than 90% as determined by immunofluorescence 23 before treatments were applied, 
except in the case of antiviral experiments, described below. 
Antiviral experiments (HCV) 
5 day time course: cells infected as described above with Jc1 at a MOI of 0.02 for 2 h were 
plated and then immediately treated with a titration of BMP6 (2-52nM) for the duration of the 
infection. Aliquots of supernatant were collected at the time points indicated. 10 day time 
course: cells infected for 2h were plated and incubated for 3 days. Cells were then sub-cultured 
and BMP6 added at 18nM. Additional doses of the same concentration were applied at further 
sub-culturing to maintain the dose. For both time courses, IFN-alpha (PBL Biomedical 
Laboratories) was added at 1000U/mL 1 day prior to the termination of the experiment. 
Supernatant RNA extraction was performed using QIAamp viral RNA extraction kit and total 
cellular RNA was extracted using RNeasy kit (both Qiagen). cDNA was then transcribed using 
the Superscript III Reverse transcriptase (Invitrogen), all according to the manufacturers’ 
protocols. HCV RNA levels were measured using qRT-PCR in a LightCycler 480 Real-Time 
PCR System (Roche). cDNA at 10-100ng/uL was amplified using RC1 (5’ GTC TAG CCA TGG 
CGT TAG TA 3’) and RC21 (5’ CTC CCG GGG CAC TCG CAA GC 3’) primers. Each reaction 
was run in duplicate. HCV RNA levels were quantified using a standard curve derived from 
HCV Jc1 cDNA. 
HCV Core staining: Huh 7.5.1 hepatoma cells (a gift from F. Chisari) were plated at 4,000 cells 
per well in 96 well plates and incubated overnight. The next day, cells were treated with BMP6 
18nM dissolved in filter sterilised 1% BSA 4mM HCl (vehicle), IFNa 12.5IU/ml (obtained from 
PBL), BMP6 18nM plus IFNa (12.5IU/ml), vehicle, or untreated. After 24 hours, 25ul of JFH1 
stock was added on top of the medium in all wells, yielding a final MOI of 1. Cells were incubated 
at 37 degrees. 4 hours later, medium containing inoculum was removed, and medium / drug 
were replaced in the same concentration as that used initially, in a well-by-well manner. Cells 
were then incubated for 48h at 37 degrees. Cells were then fixed in 4% PFA (Sigma), then 
permeabilized in 0.2% Triton, then incubated overnight with anti-core antibody at 4°C. Cells 
were then stained with goat anti mouse Alexa 488 secondary antibody (Invitrogen) for 1 hour, 
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followed by incubation in Hoechst. Cells were imaged using FITC and DAPI and images 
captured using an IXM2 automated microscope at the Harvard Longwood ICCB, and analyzed 
using MetaXpress cell scoring software (Molecular Devices 9500-0037). 
OR6 experiments: Reagents were added to OR6 cells or their IFN-cured counterparts at the 
doses and for the time specified in figure legends before being assayed using the Renilla 
Luciferase Assay System or Renilla-Glo Luciferase Assay (both Promega). Values were 
background subtracted (background: cured cells) and then normalised to the relevant untreated 
control. To monitor cell numbers in the OR6 experiments the CellTiter Glo Luminescent Cell 
Viability Assay (Promega) was used. 
Antiviral experiments (HBV) 
HepaRG cells (ThermoFisher), a HCV-negative hepatoma-derived line exhibiting both 
hepatocellular and biliary morphologies in vitro, were plated in collagen-coated 24-well plates 
at a density of 5x104cells/well. Cells were allowed to grow in medium for two weeks, before 
addition of differentiation medium containing 2% (v/v) DMSO and EGF. Cells were cultured for 
a further two weeks, before infection with a fixed inoculum of HBV [1.5-2.0 x 106 genome 
equivalents per well; corresponding to approximately 10 genome equivalents per cell]. HBV 
particles were produced and harvested from HepG2 (clone 2.2.15) hepatoblastoma cells as 
described24. Infection continued for 17-20 h at 37 °C, in the presence of 4% (v/v) PEG 8000. 
Following infection, cells were washed in medium and cultured for seven days in the presence 
of 2% (v/v) DMSO, 5 μg/mL insulin and 50 mM hydrocortisone. Cells were concurrently 
incubated with 25 μM lamivudine (Sigma Aldrich), 100 U/mL IFNα (Peprotech), BMP6 or activin 
A (both R&D Systems) at specified doses. At day 7 post-infection, culture supernatants were 
harvested and assayed for the presence of HBsAg with the MONOLISA™ Ultra HBsAg kit 
[catalogue I.D. 74326] (BioRad, Hercules, CA), in accordance with the manufacturer’s 
instructions. 
 
Antiviral experiments (ZIKV) 
A549 cells (ATCC and University Hospital Heidelberg) were seeded in a 24-well format at 
approx. 1.0x105 cells per well and incubated overnight. Cells were then pre-treated for 16 hours 
with the indicated concentrations of IFN-alpha and/or Activin A, then washed and subsequently 
inoculated with ZIKV (H/PF/2013 strain) with an MOI of 1 for 2 hours, the media was then 
replaced and the cells were incubated for 24 hours total, with fresh IFN alpha and/or Activin A 
also added. Supernatant containing ZIKV was harvested and stored at -80°C. VeroE6 cells 
(ATCC) were seeded in a 24-well format at approx. 2.5x105 cells per well and incubated 
overnight. 6 Serial dilutions (5x dilutions) of supernatant containing ZIKV were prepared per 
treatment condition and 200 µl of each dilution for each treatment was added onto the VeroE6 
cells (in duplicate) and incubated for 60 min before removal of the inoculum, and a 
carboxymethylcellulose overlay was added. VeroE6 cells were then incubated for 96 hours. 
The overlay was removed and cells were fixed with 10% PFA solution, washed, and finally 
stained with crystal violet solution for plaque visualization. A549 and VeroE6 cells were 
maintained in DMEM supplemented with 10% fetal bovine serum (FBS) 100 U/mL penicillin, 
100 μg/mL streptomycin, 2 mM L-glutamine, and 1% non-essential amino acids (all from Gibco, 
Life Technologies), and incubated at 37°C, 5.0% CO2, and 90% humidity, unless stated 
otherwise.  
Gene Expression Microarray 
The whole gene expression profile of HuH7.5 cells treated with 18nM BMP6 for 24 hours was 
compared to that of cells treated with vehicle (n= 2 independent experiments, each run in 
triplicate giving a total of 6 RNA extracts per condition) utilising Illumina’s Human HT12v4.0 
Expression BeadChip. Total mRNA was isolated using RNeasy mini kits then converted into 
labelled cRNA and used for hybridisation. The hybridised and washed chips were then scanned 
using Illumina HiScan Scanner. Illumina's Genomestudio®software was used to carry out QC 
checks of the procedure and to provide final reports. The microarray was performed in 
collaboration with the High-Throughput Genomics Group at the Wellcome Trust Centre for 
Human Genetics, University of Oxford (funded by Wellcome Trust grant reference 
090532/Z/09/Z and MRC Hub grant G0900747 91070) and the analysis carried out using the 
R statistical language with Bioconductor and the Linear Models for Microarray (LIMMA) data 
package in collaboration with the Computational Biology Research Group, University of Oxford. 
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Using an adjusted P-value cut off of P-value<0.001 (adjusted for multiple testing with Benjamini 
and Hochberg’s method) to determine significant differentially expressed genes, we obtained 
a list of 2275 transcripts, including several known direct targets of BMP signaling such as ID3, 
ID1 and HAMP. This list of transcripts was analysed using GeneGO MetaCore (Thomson 
Reuters; version 6.10 build 31731) yielding 2149 network objects, which were then analysed 
using the “Functional Ontology Enrichment Pathway Map”, with FDR set at 0.05. This analysis 
revealed that Type I IFN signaling pathway (P-value =10e-4) was statistically significantly 
altered after 24h BMP6 treatment (Supplementary Figures 2, 4). For reference the BMP 
signaling pathway was also statistically significantly altered (P-value = 10e-4).  
BrdU/PI analysis of cell cycle phase distribution 
Incorporation of the brominated nucleoside analogue 5’-bromo-2’-deoxyuridine (BrdU) during 
a pulsed exposure provides an index of DNA replication rates, whereas propidium iodide (PI) 
intercalates into DNA duplexes, allowing quantification of total cellular DNA. Flow cytometric 
analysis of immunostained BrdU and PI fluorescence yields a “horseshoe” distribution. Cells in 
G0/G1 are associated with both minimal BrdU incorporation and 1N quantity of DNA; as S-
phase proceeds increasing quantities of BrdU are incorporated and PI signal also increases; 
cells in G2/M are characterized by 2N DNA content and low BrdU signal. Huh7 cells were 
seeded at 7x104 cells/well in a 6-well plate. 24 h after seeding, cells were washed with PBS 
and replenished with DMEM10 (untreated cells), 100 nM UCN-01 Sigma-Aldrich, USA), or 
18nM recombinant human BMP6 (R&D Systems, MN, USA) in duplicate wells per condition. 
UCN-01 was first identified as protein kinase C inhibitor secreted by Streptomyces; it elicits cell 
cycle arrest in multiple cell lines via both inhibition of Rb phosphorylation and transcriptional 
induction of the cyclin-CDK inhibitor p21 and related Cip/Kip proteins25-27. 
After 48 h incubation, cells were “pulsed” for 30 minutes by addition of the synthetic thymidine 
analogue BrdU to a final molarity of 10 μM. Cells were detached with 10mM EDTA in PBS, 
duplicate wells pooled and the cells pelleted by centrifugation at 1400 rpm for 5 min. After 
fixation with 70% EtOH at 4 °C for 30min and centrifugation at 1500 rpm for 10 min, cells were 
subjected to acid denaturation by dropwise addition of 2N HCl+0.5% Triton X-100 followed by 
a 30 min incubation at room temperature. Cells were spun down in a minifuge at 2400 rpm for 
10 min. Acidic pH was neutralized by addition of 0.1 M Na2B4O7 and the cells spun down again 
at 2400 rpm for 10 min, after which the supernatant was aspirated and the cells resuspended 
in 1mL 0.5% Tween20/1% BSA in PBS. Samples were then divided into two 500 μL aliquots, 
designated “test” and “control”. Test samples were incubated with rat anti-BrdU monoclonal 
antibody (cat. number ab6326; Abcam, Cambridge, UK) at 40 μg/mL for 30 min at room 
temperature whereas control samples were exposed to the antibody diluent (0.5% 
Tween20/1% BSA) only. After centrifugation at 2400 rpm for 10 min, both test and control cells 
were incubated with 5μg/mL goat anti-rat AlexaFluor-488 conjugated polyclonal antibody (cat. 
Number ab150157) for 30 min, in the dark. Immediately before data acquisition, all cells were 
spun down at 2400 rpm for 10 minutes and resuspended in 100 μM PI in PBS for 15 min at 
room temperature. Data were acquired with a Dako CyAn ADP flow cytometer and analysed 
with FlowJo v10 (TreeStar Inc. OR, USA). 
Data analysis, statistics and reproducibility 
Data was analysed using Microsoft Excel (Microsoft Inc.) Graphpad Prism (Graphpad Software 
Inc.) and FlowJo (Treestar Inc.). Statistical analysis and graphical presentation of data was 
performed using Graphpad Prism. The statistical tests used are stated in figure legends; P<0.05 
was considered significant. Where data sets were matched, paired and repeated measures 
tests were used and where data did not fit a Gaussian distribution, equivalent non-parametric 
tests were used, or data were log-transformed for normalisation. Bonferroni post-tests were 
used to further analyse ANOVAs unless otherwise stated. 
Data availability 
The data that support the findings of this study are available from the corresponding author 
upon request. The microarray of gene expression profile of HuH7.5 cells treated with 18nM 
BMP6 for 24 hours is available at the Gene Expression Omnibus under accession number 
GSE121073. 
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Figure Legends 
 
Figure 1: HCV – BMP pathway interactions decrease hepcidin and associate with 
therapeutic outcome  
a Uninfected or HCV-infected (MOI = 0.02) Huh7.5 cells were incubated with a titration 
of BMP6 overnight; HAMP mRNA induction in response to BMP6 was significantly 
suppressed in HCV-infected cells (Mean ± SEM shown; P<0.0001: two-tailed Wilcoxon 
matched-pairs signed rank test; n=6 biologically independent experiments). 
b Patients with known treatment outcome (n=26 biologically independent samples) 
were separated by outcome (Sustained Virological Response (SVR) and Non-
Responder (NR) and compared to the control group (n=8). HAMP mRNA expression 
was reduced in both groups compared to controls whereas HJV and ID1 were 
significantly reduced only in the NR group (Geometric means +/- geometric standard 
deviations shown; one-way ANOVA on log10-transformed data: Bonferroni’s multiple 
comparison test adjusted p-values are indicated. 
c BMP target genes ID1 and HAMP mRNA were correlated across these three groups 
(Pearson correlation of log10-transformed data: r2=0.701; p<0.0001 (two-tailed); n=25 
independent samples (n=8 control, n=11 SVR, n=6 NR). 
d, e Ratio of expression of HAMP or ID1 to BMP6, derived to represent an ‘output-per-
input’ ratio (data available from n=25 independent samples: n= 8 control; n=11 SVR;; 
n=6 NR). HAMP/BMP6 was significantly reduced in NRs and SVRs; ID1/BMP6 was 
significantly reduced in NRs (boxes indicate inter-quartile range with median; whiskers 
indicate range; one-way ANOVA: Tukey’s multiple comparison test adjusted p-values 
are indicated). 
f, g BMP pathway gene enrichment is linked to HCV clearance. SNPs linked to four 
BMP-pathway genes (BMP6, ACVR1/ALK2, EVI1, SKIL, (f)) were in the top 66 GWA 
intervals associated with differential clearance of HCV (Ge et al., 2009). g The 
frequency of four genes (black dotted line) from a million randomly generated gene-
sets of similar size to the BMP pathway occurring in the 66 GWA intervals identified by 
Ge et al (Random gene-set, left), or of four BMP pathway genes occurring in a million 
randomly generated sets of 66 GWA intervals (Shifting of GWA intervals, right), was 
determined against randomized backgrounds (grey histograms), as discussed in detail 
in Supplementary Methods. 
h Changes in expression of the type I IFN pathway related genes (IFNAR2, JAK1, 
STAT2, IRF9, ISG15, IFI6) identified by microarray of Huh7.5 cells treated with BMP6 
for 24h were confirmed by qRT-PCR; BMP target gene ID3 was measured as a positive 
control (n = 2 independent experiments, each run in triplicate, giving a total of 6 RNA 
extracts per condition; plots depict mean +/- SEM fold changes relative to untreated 
cells; two-tailed unpaired t-test) 
 
 
Figure 2: Enrichment of SMAD1-bound loci proximal to IRF1-bound loci 
a Venn diagram depicting the numerical overlap in genes to which peaks derived from 
each of four peak sets (BMP4-SMAD1, IFNa-STAT1, IFNa6h-STAT2 and IFNa6h-
IRF1) are annotated. 2632 genes are in common between BMP4-SMAD1 and IFNa6h-
IRF1.  
b Venn diagram representing the numerical overlap in genes to which peaks derived 
from the BMP4-SMAD1 and IFNa6h-IRF1 peak sets, in addition to untreated K562 
cells immunoprecipitated for RNA Pol2, are annotated.  
c-e Histograms report the density of reads obtained from ChIP-seq of each 
transcription factor (TF), under the specified stimulation conditions and normalized to 
10 million reads in each case (to avoid artefacts arising from variation in dataset size), 
mapping to +/- 500bp of the genomic loci bound by the comparator transcription factor 
(IRF1 in K562 cells treated with IFNalpha for 6 hours). c The density of SMAD1 binding 
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in BMP4-treated K562 is enriched +/- 500bp around loci bound by IRF1 following 6h 
IFNalpha stimulation of K562; in cells treated with dorsomorphin, which inhibits 
SMAD1 activation, SMAD1 binding is not enriched near IRF1-binding. d The density 
of reads derived from ChIP-seq for non-BMP pathway associated transcription factors 
(ARID3A, ELK1, INI1, RAD21, XRCC4) is not enriched near IRF1-bound loci in 
unstimulated cells. e The density of reads derived from ChIPseq for the Type I IFN-
associated transcription factors STAT1 and STAT2 are enriched near IRF1-bound loci 
in IFN-alpha treated cells. 
 
 
Figure 3: BMP6 increases expression of IRF1 and IRF7 and decreases 
expression of USP18 
a The levels of IRF1, IRF7 and the canonical BMP target gene ID1 mRNA, quantified 
by qRT-PCR, in Huh7.5 cells treated for 20h with 18nM BMP6 versus untreated 
controls. Plots display mean ± SEM; two-tailed paired t-test; data summarise n=4 
independent biological experiments). 
b 1x10^5 Huh7.5 cells were plated 24h prior to treatment with LDN193189 (LDN, 
100nM), LDN + BMP6 (at 18nM), or BMP6 or IFNalpha titrations as shown; cells were 
lysed for phospho-SMAD1/5/8 or phospho –STAT1 analysis by Western Blot 30 mins 
post-stimulation. GAPDH was used as a loading control. Data are representative of 
those obtained in two independent experiments.  
c The levels of IRF1 mRNA in Huh7.5 cells treated with 2uM dorsomorphin (Dorso) or 
0.2uM LDN-193189 (LDN) 30 minutes prior to co-incubation with 18nM BMP6 for 20h 
or 1000U/mL IFN-alpha for 6h (plots display mean of log-transformed data ± SD; two-
tailed paired t-tests on log-transformed data, n=3 independent biological replicates). 
d USP18 mRNA expression in Huh7.5 cells treated with LDN-193189 (LDN, 0.2uM) or 
Ruxolitinib (Rux, 2.5uM) prior to co-incubation with BMP6 (18nM, 20h) or IFN-alpha 
(100U/mL or 1000U/mL, 6h) (Plots display mean ± SEM; repeated measures ANOVA; 
adjusted p-values from Tukey’s multiple comparison test are shown; n=3 biologically 
independent experiments). 
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Figure 4: BMP6 enhances IFN activity 
a STAT1(Y701) phosphorylation analyzed  by Phosflow in Huh7.5 cells treated with or 
without BMP6 (18nM, 18-20h) followed by IFN-alpha (100U/mL, 30 minutes). Flow 
Cytometry analysis from a representative experiment and normalized MFI from n=3 
biologically independent experiments are shown. Plots indicate means ± SEM; 
repeated measures ANOVA: Bonferroni’s multiple comparison test adjusted p-values 
are indicated. 
b TRIM14 and IFI6 mRNA expression in Huh7.5 cells co-treated with BMP6 (18nM) 
and an IFN-alpha titration for 24h. Data from n=3 biologically independent experiments 
are shown. Plots indicate means ± SEM; repeated measures ANOVA: Bonferroni’s 
multiple comparison test adjusted p-values are indicated. 
c Huh7.5 cells were plated overnight before pre-treatment for 18h with recombinant 
BMP6 (18nM) or vehicle, prior to addition of a titration of IFN-alpha; cells were lysed a 
further 4h later. Induction of the ISG MDA5 (IFIH1) was assessed by Western Blot with 
Actin used as a loading control, normalizing protein loading according to BCA assay. 
Representative of n=3 biologically independent experiments.  
d, e Luciferase activity in OR6 cells (that harbor an HCV-replicon linked to luciferase) 
treated with or without BMP6 (2nM or 18nM, 24h) followed by addition of a titration of 
IFN-alpha (10-1000U/mL (d)) or IFN-lambda3 (2.5-100ng/mL (e)) for 20h. Data from 
n=3 biologically independent experiments in each case are shown. Plots indicate 
means ± SEM; repeated measures ANOVA: Bonferroni’s multiple comparison test 
adjusted p-values are indicated. 
f Huh7.5.1 cells were incubated with BMP6 (18nM), IFNalpha (12.5IU/mL) or BMP6 
plus IFNalpha for 24h, and then JFH1 HCV at MOI of 1 was added for 4h. Media was 
then removed and cytokines (but no virus) were re-added at the same concentrations 
for a further 48h before the percentage of HCV infected cells in the culture was 
determined by immunofluorescence for HCV core protein. Data from n=3 biologically 
independent experiments; plots depict geometric mean +/- geometric SD; repeated 
measures one-way ANOVA comparing log-transformed Vehicle, BMP6, IFNa and 
BMP6+IFNa data: Bonferroni’s multiple comparison test adjusted p-values are 
indicated. 
 
Figure 5: BMPs and Activins are antiviral against HCV  
a Left – HCV RNA in supernatants of Huh7.5 cells incubated with a titration of BMP6 
(2-52nM) was reduced in BMP6-treated cultures. Plots depict mean +/- SEM. Data 
from n=3 biologically independent experiments. Right – Supernatant HCV RNA at 5 
days post-infection was significantly lower in cultures treated with BMP6 for the 
duration of the infection. Administration of 1000U/mL IFN-alpha 1 day prior to RNA 
extraction also resulted in a significant reduction in supernatant HCV RNA. Data from 
n=4 independent experiments (n=3 only available for certain conditions). Plots depict 
mean +/- SEM; One-way ANOVA: Bonferroni’s multiple comparison test adjusted p-
values comparing with untreated are indicated. 
b Levels of supernatant and cellular HCV RNA 10 days post-infection were lower in 
cells treated with 18nM BMP6 for the last 7 days or 1000U/mL IFN-alpha for 1 day 
compared to untreated infected cells. Data from n=3 biologically independent 
experiments are shown. Plots indicate means ± SEM; repeated measures ANOVA: 
Bonferroni’s multiple comparison test adjusted p-values with respect to untreated cells 
are indicated. 
c Timecourse of luciferase activity in OR6 cells treated with 18nM BMP6 or 1000U/mL 
IFN-alpha. Data from n=3 biologically independent experiments are shown. Plots 
indicate means ± SEM; repeated measures ANOVA; Bonferroni’s multiple comparison 
test adjusted p-values with respect to untreated cells from the same timepoint are 
indicated. 
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d Luciferase activity 72h in OR6 cells treated with 2uM dorsomorphin or 0.2uM LDN-
193189 for 30 minutes prior to addition of 18nM BMP6 for 72h. Data from n=4 
biologically independent experiments are shown. Plots indicate means ± SEM; p-
values from two-tailed paired t tests are shown.  
e Left - Luciferase activity in OR6 cells pre-treated with a blocking anti-IFNAR2 
antibody or isotype control (25ug/mL) for 1h followed by addition of 18nM BMP6 or 
10U/ml IFN-alpha measured 72 h after BMP6/IFN-alpha administration. Data from n=3 
biologically independent experiments are shown. Right - luciferase activity in OR6 cells 
pre-treated with 2.5uM Ruxolitinib for 1 h prior to co-incubation with 18nM BMP6 or 
100U/mL IFN-alpha, measured 72 h after BMP6/IFN-alpha administration. Data from 
n=4 biologically independent experiments are shown. Plots indicate means ± SEM; 
repeated measures ANOVA: Bonferroni’s multiple comparison test adjusted p-values 
are indicated. 
f Luciferase activity in OR6 cells after 72h treatment with 18nM BMP6 or a dose 
titration of Activin A or Activin B. Data from n=3 biologically independent experiments 
each carried out in triplicate; Plots indicate means ± SEM; repeated measures ANOVA: 
Bonferroni’s multiple comparison test adjusted p-values with respect to untreated cells 
are indicated. 
 
 
Figure 6 Effects of BMP6 and Activin A against HBV and ZIKV 
a HepaRG cells were infected with a fixed inoculum of HBV and incubated for seven 
days in the presence of lamivudine 25 uM, recombinant human IFNα 1000U/mL or 
recombinant human BMP6 at 18nM, 52nM (Left) or Activin A at 10nM (Right). At the 
endpoint, supernatants were assayed by ELISA for Hepatitis B surface antigen 
(HBsAg) and normalized to untreated infected cells run concurrently. Data represent 
(left) n=5-10 replicate treatments run across n=4 separate days, and (right) n=12-15 
replicate treatments run across multiple days. One way ANOVA; Bonferroni’s multiple 
comparison test adjusted p-values, comparing with untreated, are indicated. 
b-e A549 cells were pre-treated for 16 hours with the indicated concentrations of IFN-
alpha and/or Activin A, then washed and noculated with ZIKV (H/PF/2013 strain) at an 
MOI of 1 for 2 hours. Medium was then replaced and the cells were incubated for 
another 24 hours in the presence of fresh IFN-alpha and/or Activin A. Supernatants 
were harvested and viral titres were assessed by plaque assay on VeroE6 cells. Data 
from n=3 biologically independent experiments: results are shown individually (black, 
red and blue lines) to adequately represent experimental variability and general trends. 
Data is shown as absolute titres (pfu/ml) (b, d) or expressed as fold changes to 
compensate for experimental variability (c, e). Two-tailed ratio paired t-tests of three 
independent experiments were performed; p-values are indicated. 
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Supplementary Table 1: Clinical parameters of control and HCV patients 
a Fibrosis data is reported as follows: 0 = no fibrosis; mild = METAVIR 1-2 and Ishak 
1-3; severe = METAVIR 3-4 and Ishak 4-6. 
b Treatment outcome is reported as follows: SVR = HCV RNA negative 6 months 
post completion of therapy; NR = HCV RNA positive 6 months post therapy 
c Missing patient information – data unavailable. 
	 	
 Controls 
N=8 
SVR b 
N=17 
NR b 
N=9 
Age (yr). mean (95% 
CI) 
67.4 (53.9 – 81.0), 
n=7c 
36.8 (31.5 – 42.0), 
n=16 c 
43.7 (37.3 – 50.1) 
Sex (M/F) 8 / 0 9 / 8 4 / 5 
Viral load (IU/mL), 
mean (95% CI) 
- 1.06  x 106 (4.97 x 
105 – 1.61 x 106), 
n=16 c 
9.77 x 105 (4.67 x 
104 – 1.91 x 106), 
n=8 c 
HCV genotype (1 / 3) - 11 / 6 7 / 2 
Fibrosis stage (0 / 
mild / severe)a 
- 10 / 7 / 0 3 / 6 / 0 
	 2	
Extracellular ligands and inhibitors BMP2, 4, 5, 6, 7, 9; Activin A, B, E; 
Noggin, Chordin, Follistatin 
Cell surface receptors and co-receptor ACVRL1, ACVR1, BMPR1A, BMPR1B 
ACVR2A, ACVR2B, BMPR2; HJV 
Intracellular signal transduction factors, 
inhibitors, and key target genes 
SMAD1, 4, 5, 6, 7, 8; SMURF1, 2, SKI, 
SKIL; EVI1; HAMP, ID1 
 
Supplementary Table 2: BMP/Activin/hepcidin related signaling pathway 
components used for GWA enrichment analysis. 
The general principles of BMP/SMAD signaling have been well explored and are the 
subject of ongoing study1-4. Here we focus on key BMP signaling components 
including those that have been shown to have in vivo effects on hepcidin regulation5. 
BMP ligands bind to the Type I BMP receptors BMPR1A (ALK3), BMPR1B (ALK6), 
ACVR1 (ALK2), and/or ACVRL1 (ALK1). Additionally, the BMP co-receptor HJV can 
recruit BMP2, BMP4, BMP5, BMP6 and BMP7 (but probably not BMP9)6,7. Noggin 
and chordin bind to BMPs and prevent them from binding to receptors. Activins A, B 
and E bind different type I receptors ACVR1B (ALK4) and ACVR1C (ALK7), although 
Activin B also utilizes BMP type I receptors in hepatocytes8. Activins are prevented 
from binding to their receptors by Follistatin. 
After ligand binding, the ligand-receptor complexes (or ligand-HJV complexes) bind 
to the BMP type II receptors BMPR2, ACVR2A, and/or ACVR2B, (Activins only bind 
ACVR2A and ACVR2B) and the type II receptors phosphorylate type I receptors 
(which may displace HJV in endosomes). Activated BMP type I receptors BMPR1A, 
BMPR1B, ACVR1, and ACVR1L then bind and phosphorylate SMAD1, SMAD5 and 
SMAD8 (also known as SMAD9), together known as BMP R-SMADs. Activin type I 
receptors (ACVR1B and ACVR1C) bind and phosphorylate a different subset of R-
SMAD proteins (SMAD2 and SMAD3), although Activin B can also signal through 
SMAD1, 5 or 8 in hepatocytes8. R-SMADs then bind to another SMAD, SMAD4. R-
SMAD-SMAD4 complexes go to the nucleus and bind promoters of target genes, 
including SMAD6 and SMAD7. The encoded SMAD6 and SMAD7 proteins inhibit 
BMP signalling; SMAD6 binding targets include BMPR1B, inhibiting downstream 
phosphorylation of SMAD1 and SMAD5, while SMAD7 can bind to BMPR1A, 
BMPR1B and ACVR1, also inhibiting phosphorylation of SMAD1 and SMAD5. 
SMURF1 binds SMAD6 and SMAD7 and causes the ubiquitination and degradation 
of SMAD1, SMAD5, BMPR1B. SMURF2 can target SMAD1 for degradation. SKI, 
SKIL and EVI1 interact with SMAD1, SMAD5 and SMAD4 and repress BMP 
signalling. BMPs and Activin B induce expression of ID1 and HAMP in the liver. 
 
Not included in the list are FOXG1 and GRIP1, which are not generally regarded as 
being part of the BMP signaling pathway; although both have been shown to regulate 
BMP signaling9,10. Several SNPs linked with FOXG1 and GRIP1 were also reported 
in the top 100 SNPs associated with differential HCV clearance 11. Therefore there 
may be further significant enrichment of BMP-pathway variation associated with 
outcome of antiviral treatment of HCV. 
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ISG upregulated 
by BMP6 
 
Effect of overexpression  
on HCV replication at 72h 
(see ref 21 of main ms) 
 
ISG downregulated by 
BMP6 
  
Effect of overexpression  
on HCV replication at 72h 
(see ref 21 of main ms) 
 
JUNB anti ARG2  anti  
IRF9 anti GK  anti  
LGALS3 anti IL28RA  anti  
HLA-E anti IMPA2  anti  
ADM anti ZNF385B  anti  
PSCD1 anti IL1RN  anti  
SSBP3 anti THOC4  anti  
PFKFB3 anti GCH1  anti  
LGMN anti PDGFRL  anti  
CASP7 anti USP18  anti  
MAFB anti CCDC109B  anti  
BLVRA anti VAMP5  anti  
IFNGR1 anti DUSP5  anti  
TBX3 anti C10orf10  anti  
IFI6 anti PUS1  pro  
GLRX anti ETV6  pro  
SOCS2 anti CXCL10  pro  
TMEM51 anti CPT1A  pro  
HK2 anti IL17RB  pro  
FAM125B anti ENPP1  pro  
CCDC92 anti MASTL  pro  
ISG15 anti RIPK2  pro  
UBE2L6 anti RNASE4  pro  
SERPING1 anti CD38  pro  
TDRD7 anti GPX2  pro  
SPSB1 anti FAM46A  pro  
TRIM5 anti     
CDKN1A anti     
HEG1 anti     
STAT2 anti     
IFI6 pro     
TXNIP pro     
CD9 pro     
SP110 pro     
BCL3 pro     
AXUD1 pro     
	
Supplementary Table 3: Effect of BMP6 on expression of ISGs with known 
influence on HCV replication in vitro. We assessed the effect of BMP6 on 
expression of 355 known ISGs using our microarray of BMP6-treated HuH7.5 cells, 
in which 2275 genes were differentially expressed. The 355 ISGs chosen have been 
individually investigated for their effect on HCV replication in HuH7.5 cells (ref 21 of 
main ms, Schoggins et al Nature 2011). We found that BMP6 upregulated 36 of the 
355 ISGs (30 of these 36 inhibited HCV replication in Schoggins et al ‘anti’) and 
downregulated 26 ISGs (14 of these 26 inhibited HCV replication in Schoggins et al). 
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Dataset 
NCBI GEO 
Accession ID 
ENCODE  
Accession ID 
Cell 
type Condition Antibody 
BMP4-SMAD1 GSM722416   K562 
Human BMP4 
@25ng/µL for 2h SMAD1 
IFNa6h-IRF1   wgEncodeEH001865 K562 Human IFNα; 6h IRF1 
Input control GSM935363 wgEncodeEH000615 K562 Unstimulated IgG 
None-ARID3A GSM935336 wgEncodeEH002861 K562 Unstimulated ARID3A 
None-ELK1   wgEncodeEH003356 K562 Unstimulated ELK1 
None-INI1 GSM935634 wgEncodeEH000725 K562 Unstimulated INI1 
None-RAD21 GSM935319 wgEncodeEH000649 K562 Unstimulated RAD21 
None-XRCC4 GSM935425 wgEncodeEH000650 K562 Unstimulated XRCC4 
Dorso-SMAD1 GSM722417   K562 
Dorsomorphin 
@20 µM for 2h SMAD1 
IFNa6h-
STAT1   wgEncodeEH000664 K562 Human IFNα; 6h STAT1 
IFNa6h-
STAT2   wgEncodeEH000666 K562 Human IFNα; 6h STAT2 
None-RNA Pol 
II   wgEncodeEH000616 K562 Unstimulated Pol2 
None-RNA Pol 
III GSM935481 wgEncodeEH000694 K562 Unstimulated Pol3 
CD34+ BMP4-
SMAD1 GSM722399   CD34+  
Human BMP4 
@25ng/µL for 2h SMAD1 
U937 BMP4-
SMAD1 GSM722425   U937 
Human BMP4 
@25ng/µL for 2h SMAD1 
CD34+ Input 
Control GSM1097886   CD34+  Unstimulated N/a 
U937 Whole 
Cell Extract GSM722431   U937 Unstimulated N/a 
	
Supplementary Table 4: ChIP-seq datasets interrogated in this study 
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GO BP: type I IFN-mediated signalling pathway 
Genes Genomic Regions of Peaks 
ADAR 
chr1-2962 (-255635), chr1-1314 (-232445), chr1-5863 (-183715), chr1-1879 (-143724), 
chr1-3393 (-140074), chr1-4957 (-127712), chr1-2708 (-125585), chr1-5862 (-120979), 
chr1-554 (-112803), chr1-3607 (-111619), chr1-3092 (-106847), chr1-4956 (-17182), chr1-
2825 (-15313), chr1-4036 (+33277) 
EGR1 chr5-770 (-6920) 
GBP2 chr1-4884 (-3979), chr1-3992 (-1115), chr1-5308 (-42) 
HLA-A chr6-2198 (-24431), chr6-336 (+22554), chr6-4512 (+39815) 
HLA-C chr6-2326 (+42784), chr6-849 (+55692), chr6-848 (+68097), chr6-2465 (+69094) 
HLA-F chr6-1069 (+11466), chr6-1772 (+39500), chr6-2948 (+40502) 
HLA-G chr6-2198 (+91060) 
IFI35 chr17-502 (+7726), chr17-288 (+12451) 
IFI6 chr1-698 (+9361), chr1-4186 (+13152) 
IFIT1 chr10-694 (-7434), chr10-1229 (-104), chr10-1173 (+662) 
IFIT2 
chr10-3018 (-42885), chr10-404 (-6079), chr10-801 (-5415), chr10-830 (-443), chr10-1550 
(+208), chr10-3019 (+24268) 
IFIT3 
chr10-3019 (-6265), chr10-1551 (-4537), chr10-693 (-4148), chr10-1718 (-64), chr10-1933 
(+529), chr10-1279 (+1019), chr10-1124 (+14105) 
IFNA1 chr9-953 (-28049), chr9-203 (+4001) 
IFNA13 chr9-408 (-13802), chr9-2012 (+10100) 
IFNA14 
chr9-1830 (-55392), chr9-2181 (-55103), chr9-2413 (-47602), chr9-611 (-13485), chr9-2180 
(-12475) 
IFNA2 chr9-342 (-105), chr9-408 (+3519) 
IFNA21 chr9-590 (+6282), chr9-818 (+13138) 
IFNA5 
chr9-1831 (-18046), chr9-1830 (+9942), chr9-2181 (+10231), chr9-2413 (+17732), chr9-
611 (+51849), chr9-2180 (+52859) 
IFNA6 chr9-2012 (-7089) 
IFNA8 chr9-953 (+3258) 
IFNAR1 
chr21-896 (-86537), chr21-651 (-86118), chr21-455 (-82878), chr21-136 (-80679), chr21-
343 (-79919), chr21-88 (-77092), chr21-173 (-64686), chr21-17 (-63130), chr21-180 (-
59081), chr21-318 (-23775), chr21-373 (-23381), chr21-381 (-20104), chr21-181 (-15861), 
chr21-690 (-7671), chr21-344 (+37319), chr21-319 (+43371), chr21-802 (+49352), chr21-
616 (+49639), chr21-63 (+55134), chr21-155 (+55806), chr21-306 (+58503), chr21-16 
(+69524) 
IFNAR2 
chr21-217 (-150743), chr21-190 (-140306), chr21-688 (-133282), chr21-191 (-128529), 
chr21-154 (-120018), chr21-134 (-104800), chr21-275 (-101233), chr21-104 (-31015), 
chr21-475 (-26007), chr21-56 (-14144), chr21-290 (-13636), chr21-896 (+8446), chr21-651 
(+8865), chr21-455 (+12105), chr21-136 (+14304), chr21-343 (+15064), chr21-88 
(+17891), chr21-173 (+30297), chr21-17 (+31853), chr21-180 (+35902), chr21-318 
(+71208), chr21-373 (+71602), chr21-381 (+74879), chr21-181 (+79122), chr21-690 
(+87312) 
IFNB1 
chr9-784 (-41364), chr9-881 (-27009), chr9-1573 (-20031), chr9-842 (-19161), chr9-463 (-
4245), chr9-988 (+16642), chr9-1684 (+30233) 
IP6K2 chr3-2342 (-127879), chr3-3483 (-94900) 
IRF1 
chr5-2856 (-34641), chr5-2610 (-6287), chr5-2609 (-5116), chr5-1960 (+11297), chr5-545 
(+22954), chr5-146 (+24117), chr5-461 (+33262), chr5-734 (+34144), chr5-2608 (+53010), 
chr5-1318 (+62891), chr5-70 (+64056), chr5-689 (+67890), chr5-639 (+69659), chr5-2607 
(+75956), chr5-2385 (+100871), chr5-1851 (+102947) 
IRF2 
chr4-929 (-60206), chr4-550 (-39937), chr4-286 (-29648), chr4-1512 (-5256), chr4-1785 (-
142), chr4-2439 (+13540), chr4-1318 (+20978), chr4-1027 (+22595), chr4-2154 (+56500), 
chr4-1388 (+78482), chr4-454 (+79576), chr4-810 (+90425), chr4-1952 (+91834), chr4-241 
(+119227), chr4-928 (+127211), chr4-2153 (+128953), chr4-1511 (+160081), chr4-1951 
(+180832), chr4-608 (+244268) 
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IRF4 
chr6-753 (-94869), chr6-257 (-92958), chr6-1995 (-78550), chr6-792 (-54863), chr6-909 (-
52064), chr6-344 (-50391), chr6-1370 (-19001), chr6-1171 (-7085), chr6-1093 (+31227), 
chr6-733 (+33605), chr6-1094 (+35070), chr6-1280 (+35405), chr6-3119 (+40552), chr6-
2903 (+43050), chr6-2169 (+83260), chr6-1911 (+107431), chr6-2904 (+219305) 
IRF5 
chr7-1422 (-13764), chr7-2681 (-12976), chr7-608 (+2745), chr7-409 (+3314), chr7-64 
(+10756), chr7-191 (+11197), chr7-1242 (+75618), chr7-549 (+76956) 
IRF6 
chr1-4097 (-2056), chr1-284 (+36621), chr1-1488 (+37715), chr1-1895 (+38255), chr1-
3457 (+44989) 
IRF7 chr11-2015 (-1071) 
IRF8 
chr16-2 (-69256), chr16-1902 (-60570), chr16-663 (-47490), chr16-43 (-45301), chr16-789 
(-42945), chr16-2127 (-25847), chr16-1903 (-24928), chr16-1333 (-10194), chr16-313 
(+6270), chr16-13 (+29458), chr16-486 (+37110), chr16-935 (+37415), chr16-218 
(+44738), chr16-233 (+79109), chr16-50 (+83593), chr16-40 (+84591), chr16-301 
(+85262), chr16-1906 (+97802), chr16-170 (+111845), chr16-688 (+115456), chr16-1242 
(+118794), chr16-147 (+119570), chr16-1337 (+191041), chr16-790 (+270369), chr16-1107 
(+314056), chr16-1568 (+408059), chr16-936 (+420984), chr16-664 (+442082), chr16-638 
(+454231), chr16-1442 (+456832), chr16-260 (+480400), chr16-1338 (+516377), chr16-566 
(+549124), chr16-882 (+549527) 
ISG20 chr15-2334 (-16253), chr15-2862 (-15528), chr15-931 (-59) 
JAK1 
chr1-370 (-130792), chr1-1606 (-89499), chr1-5736 (-88169), chr1-4868 (+9703), chr1-
5287 (+32060), chr1-3362 (+33046), chr1-4239 (+49056), chr1-4867 (+68281), chr1-1995 
(+70830), chr1-1866 (+102235), chr1-7092 (+220013) 
MX1 chr21-219 (-29419), chr21-261 (-5780) 
MX2 chr21-370 (+14), chr21-219 (+34609), chr21-261 (+58248) 
OAS1 
chr12-3290 (-50853), chr12-795 (-36159), chr12-250 (-19252), chr12-3693 (-13867), chr12-
764 (-57), chr12-1227 (+603) 
OAS2 chr12-2145 (-38339), chr12-928 (-64), chr12-1121 (+62301) 
OAS3 chr12-2145 (+1686) 
OASL 
chr12-3010 (-71387), chr12-931 (-57537), chr12-1124 (-56690), chr12-735 (-53984), chr12-
3317 (-48933), chr12-1231 (-10627), chr12-2736 (+2168), chr12-1176 (+4879) 
PSMB8 chr6-543 (-1622), chr6-2470 (-1186) 
PTPN1 
chr20-35 (-288668), chr20-1004 (-249610), chr20-480 (-239621), chr20-110 (-238049), 
chr20-312 (-235277), chr20-548 (-226294), chr20-245 (-212650), chr20-209 (-207799), 
chr20-246 (-171500), chr20-654 (-163639), chr20-189 (-162120), chr20-101 (-160896), 
chr20-257 (-156696), chr20-1254 (-143608), chr20-584 (-138063), chr20-76 (-130955), 
chr20-1087 (-128016), chr20-1324 (-124192), chr20-2181 (-106582), chr20-247 (-100603), 
chr20-508 (-97107), chr20-328 (-75497), chr20-786 (-69721), chr20-496 (-69325), chr20-
463 (-59340), chr20-105 (-54370), chr20-1191 (-52322), chr20-787 (+6445), chr20-481 
(+7600), chr20-58 (+31467), chr20-1192 (+62830), chr20-1632 (+126717), chr20-1193 
(+130618), chr20-266 (+142443), chr20-443 (+200475) 
PTPN11 chr12-1782 (+28612), chr12-1226 (+163632), chr12-794 (+181381) 
PTPN6 
chr12-3057 (-3014), chr12-2329 (-2608), chr12-1135 (+4704), chr12-536 (+7409), chr12-
1915 (+12303), chr12-347 (+12665), chr12-2330 (+15293) 
RNASEL 
chr1-1955 (+48911), chr1-6620 (+68398), chr1-67 (+104425), chr1-512 (+128556), chr1-
1775 (+129068) 
SOCS1 
chr16-1602 (-9533), chr16-1122 (-8276), chr16-642 (+19017), chr16-999 (+21978), chr16-
455 (+22959), chr16-454 (+36801), chr16-641 (+47142), chr16-593 (+49998), chr16-469 
(+54091), chr16-1057 (+74068), chr16-1951 (+110583), chr16-1950 (+117312), chr16-1266 
(+119379), chr16-570 (+120608), chr16-1180 (+127211), chr16-1056 (+129345), chr16-
1756 (+131751), chr16-468 (+151066), chr16-354 (+161741), chr16-998 (+162078), chr16-
362 (+173235), chr16-291 (+176443), chr16-1265 (+189563), chr16-70 (+203644), chr16-
668 (+205101), chr16-890 (+207296), chr16-1755 (+221342), chr16-547 (+221972), chr16-
1357 (+260483), chr16-1055 (+306607), chr16-438 (+322882), chr16-799 (+370750), 
chr16-723 (+374370) 
SOCS3 
chr17-826 (+16249), chr17-1223 (+22384), chr17-51 (+30513), chr17-525 (+35276), chr17-
1950 (+65135), chr17-2529 (+65997), chr17-2119 (+66730), chr17-2756 (+67237), chr17-
1827 (+74770), chr17-2118 (+75749) 
SP100 
chr2-2369 (-3570), chr2-1251 (+19), chr2-4992 (+2390), chr2-4993 (+23702), chr2-190 
(+41431), chr2-6135 (+162016), chr2-3944 (+173551), chr2-475 (+227527), chr2-1817 
(+227979), chr2-319 (+244660), chr2-1121 (+252511), chr2-4996 (+253022), chr2-4193 
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(+262424), chr2-2680 (+284442) 
STAT1 
chr2-3280 (-100570), chr2-4931 (-37861), chr2-4508 (-24304), chr2-3911 (-6895), chr2-
1929 (+17051), chr2-841 (+43193), chr2-2932 (+52159), chr2-3279 (+66201), chr2-3910 
(+122614) 
STAT2 chr12-2875 (+1157) 
TYK2 chr19-577 (+7643) 
USP18 chr22-9 (-35843), chr22-503 (-30016) 
XAF1 chr17-341 (-3177), chr17-774 (-2667), chr17-3083 (+40776) 
  
GO BP: response to type I IFN 
Genes Genomic Regions of Peaks 
ADAR 
chr1-2962 (-255635), chr1-1314 (-232445), chr1-5863 (-183715), chr1-1879 (-143724), 
chr1-3393 (-140074), chr1-4957 (-127712), chr1-2708 (-125585), chr1-5862 (-120979), 
chr1-554 (-112803), chr1-3607 (-111619), chr1-3092 (-106847), chr1-4956 (-17182), chr1-
2825 (-15313), chr1-4036 (+33277) 
EGR1 chr5-770 (-6920) 
GBP2 chr1-4884 (-3979), chr1-3992 (-1115), chr1-5308 (-42) 
HLA-A chr6-2198 (-24431), chr6-336 (+22554), chr6-4512 (+39815) 
HLA-C chr6-2326 (+42784), chr6-849 (+55692), chr6-848 (+68097), chr6-2465 (+69094) 
HLA-F chr6-1069 (+11466), chr6-1772 (+39500), chr6-2948 (+40502) 
HLA-G chr6-2198 (+91060) 
IFI35 chr17-502 (+7726), chr17-288 (+12451) 
IFI6 chr1-698 (+9361), chr1-4186 (+13152) 
IFIT1 chr10-694 (-7434), chr10-1229 (-104), chr10-1173 (+662) 
IFIT2 
chr10-3018 (-42885), chr10-404 (-6079), chr10-801 (-5415), chr10-830 (-443), chr10-1550 
(+208), chr10-3019 (+24268) 
IFIT3 
chr10-3019 (-6265), chr10-1551 (-4537), chr10-693 (-4148), chr10-1718 (-64), chr10-1933 
(+529), chr10-1279 (+1019), chr10-1124 (+14105) 
IFNA1 chr9-953 (-28049), chr9-203 (+4001) 
IFNA13 chr9-408 (-13802), chr9-2012 (+10100) 
IFNA14 
chr9-1830 (-55392), chr9-2181 (-55103), chr9-2413 (-47602), chr9-611 (-13485), chr9-2180 
(-12475) 
IFNA2 chr9-342 (-105), chr9-408 (+3519) 
IFNA21 chr9-590 (+6282), chr9-818 (+13138) 
IFNA5 
chr9-1831 (-18046), chr9-1830 (+9942), chr9-2181 (+10231), chr9-2413 (+17732), chr9-
611 (+51849), chr9-2180 (+52859) 
IFNA6 chr9-2012 (-7089) 
IFNA8 chr9-953 (+3258) 
IFNAR1 
chr21-896 (-86537), chr21-651 (-86118), chr21-455 (-82878), chr21-136 (-80679), chr21-
343 (-79919), chr21-88 (-77092), chr21-173 (-64686), chr21-17 (-63130), chr21-180 (-
59081), chr21-318 (-23775), chr21-373 (-23381), chr21-381 (-20104), chr21-181 (-15861), 
chr21-690 (-7671), chr21-344 (+37319), chr21-319 (+43371), chr21-802 (+49352), chr21-
616 (+49639), chr21-63 (+55134), chr21-155 (+55806), chr21-306 (+58503), chr21-16 
(+69524) 
IFNAR2 
chr21-217 (-150743), chr21-190 (-140306), chr21-688 (-133282), chr21-191 (-128529), 
chr21-154 (-120018), chr21-134 (-104800), chr21-275 (-101233), chr21-104 (-31015), 
chr21-475 (-26007), chr21-56 (-14144), chr21-290 (-13636), chr21-896 (+8446), chr21-651 
(+8865), chr21-455 (+12105), chr21-136 (+14304), chr21-343 (+15064), chr21-88 
(+17891), chr21-173 (+30297), chr21-17 (+31853), chr21-180 (+35902), chr21-318 
(+71208), chr21-373 (+71602), chr21-381 (+74879), chr21-181 (+79122), chr21-690 
(+87312) 
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IFNB1 
chr9-784 (-41364), chr9-881 (-27009), chr9-1573 (-20031), chr9-842 (-19161), chr9-463 (-
4245), chr9-988 (+16642), chr9-1684 (+30233) 
IP6K2 chr3-2342 (-127879), chr3-3483 (-94900) 
IRF1 
chr5-2856 (-34641), chr5-2610 (-6287), chr5-2609 (-5116), chr5-1960 (+11297), chr5-545 
(+22954), chr5-146 (+24117), chr5-461 (+33262), chr5-734 (+34144), chr5-2608 (+53010), 
chr5-1318 (+62891), chr5-70 (+64056), chr5-689 (+67890), chr5-639 (+69659), chr5-2607 
(+75956), chr5-2385 (+100871), chr5-1851 (+102947) 
IRF2 
chr4-929 (-60206), chr4-550 (-39937), chr4-286 (-29648), chr4-1512 (-5256), chr4-1785 (-
142), chr4-2439 (+13540), chr4-1318 (+20978), chr4-1027 (+22595), chr4-2154 (+56500), 
chr4-1388 (+78482), chr4-454 (+79576), chr4-810 (+90425), chr4-1952 (+91834), chr4-241 
(+119227), chr4-928 (+127211), chr4-2153 (+128953), chr4-1511 (+160081), chr4-1951 
(+180832), chr4-608 (+244268) 
IRF4 
chr6-753 (-94869), chr6-257 (-92958), chr6-1995 (-78550), chr6-792 (-54863), chr6-909 (-
52064), chr6-344 (-50391), chr6-1370 (-19001), chr6-1171 (-7085), chr6-1093 (+31227), 
chr6-733 (+33605), chr6-1094 (+35070), chr6-1280 (+35405), chr6-3119 (+40552), chr6-
2903 (+43050), chr6-2169 (+83260), chr6-1911 (+107431), chr6-2904 (+219305) 
IRF5 
chr7-1422 (-13764), chr7-2681 (-12976), chr7-608 (+2745), chr7-409 (+3314), chr7-64 
(+10756), chr7-191 (+11197), chr7-1242 (+75618), chr7-549 (+76956) 
IRF6 
chr1-4097 (-2056), chr1-284 (+36621), chr1-1488 (+37715), chr1-1895 (+38255), chr1-
3457 (+44989) 
IRF7 chr11-2015 (-1071) 
IRF8 
chr16-2 (-69256), chr16-1902 (-60570), chr16-663 (-47490), chr16-43 (-45301), chr16-789 
(-42945), chr16-2127 (-25847), chr16-1903 (-24928), chr16-1333 (-10194), chr16-313 
(+6270), chr16-13 (+29458), chr16-486 (+37110), chr16-935 (+37415), chr16-218 
(+44738), chr16-233 (+79109), chr16-50 (+83593), chr16-40 (+84591), chr16-301 
(+85262), chr16-1906 (+97802), chr16-170 (+111845), chr16-688 (+115456), chr16-1242 
(+118794), chr16-147 (+119570), chr16-1337 (+191041), chr16-790 (+270369), chr16-1107 
(+314056), chr16-1568 (+408059), chr16-936 (+420984), chr16-664 (+442082), chr16-638 
(+454231), chr16-1442 (+456832), chr16-260 (+480400), chr16-1338 (+516377), chr16-566 
(+549124), chr16-882 (+549527) 
ISG20 chr15-2334 (-16253), chr15-2862 (-15528), chr15-931 (-59) 
JAK1 
chr1-370 (-130792), chr1-1606 (-89499), chr1-5736 (-88169), chr1-4868 (+9703), chr1-
5287 (+32060), chr1-3362 (+33046), chr1-4239 (+49056), chr1-4867 (+68281), chr1-1995 
(+70830), chr1-1866 (+102235), chr1-7092 (+220013) 
MX1 chr21-219 (-29419), chr21-261 (-5780) 
MX2 chr21-370 (+14), chr21-219 (+34609), chr21-261 (+58248) 
OAS1 
chr12-3290 (-50853), chr12-795 (-36159), chr12-250 (-19252), chr12-3693 (-13867), chr12-
764 (-57), chr12-1227 (+603) 
OAS2 chr12-2145 (-38339), chr12-928 (-64), chr12-1121 (+62301) 
OAS3 chr12-2145 (+1686) 
OASL 
chr12-3010 (-71387), chr12-931 (-57537), chr12-1124 (-56690), chr12-735 (-53984), chr12-
3317 (-48933), chr12-1231 (-10627), chr12-2736 (+2168), chr12-1176 (+4879) 
PSMB8 chr6-543 (-1622), chr6-2470 (-1186) 
PTPN1 
chr20-35 (-288668), chr20-1004 (-249610), chr20-480 (-239621), chr20-110 (-238049), 
chr20-312 (-235277), chr20-548 (-226294), chr20-245 (-212650), chr20-209 (-207799), 
chr20-246 (-171500), chr20-654 (-163639), chr20-189 (-162120), chr20-101 (-160896), 
chr20-257 (-156696), chr20-1254 (-143608), chr20-584 (-138063), chr20-76 (-130955), 
chr20-1087 (-128016), chr20-1324 (-124192), chr20-2181 (-106582), chr20-247 (-100603), 
chr20-508 (-97107), chr20-328 (-75497), chr20-786 (-69721), chr20-496 (-69325), chr20-
463 (-59340), chr20-105 (-54370), chr20-1191 (-52322), chr20-787 (+6445), chr20-481 
(+7600), chr20-58 (+31467), chr20-1192 (+62830), chr20-1632 (+126717), chr20-1193 
(+130618), chr20-266 (+142443), chr20-443 (+200475) 
PTPN11 chr12-1782 (+28612), chr12-1226 (+163632), chr12-794 (+181381) 
PTPN6 
chr12-3057 (-3014), chr12-2329 (-2608), chr12-1135 (+4704), chr12-536 (+7409), chr12-
1915 (+12303), chr12-347 (+12665), chr12-2330 (+15293) 
RNASEL 
chr1-1955 (+48911), chr1-6620 (+68398), chr1-67 (+104425), chr1-512 (+128556), chr1-
1775 (+129068) 
	 9	
SOCS1 
chr16-1602 (-9533), chr16-1122 (-8276), chr16-642 (+19017), chr16-999 (+21978), chr16-
455 (+22959), chr16-454 (+36801), chr16-641 (+47142), chr16-593 (+49998), chr16-469 
(+54091), chr16-1057 (+74068), chr16-1951 (+110583), chr16-1950 (+117312), chr16-1266 
(+119379), chr16-570 (+120608), chr16-1180 (+127211), chr16-1056 (+129345), chr16-
1756 (+131751), chr16-468 (+151066), chr16-354 (+161741), chr16-998 (+162078), chr16-
362 (+173235), chr16-291 (+176443), chr16-1265 (+189563), chr16-70 (+203644), chr16-
668 (+205101), chr16-890 (+207296), chr16-1755 (+221342), chr16-547 (+221972), chr16-
1357 (+260483), chr16-1055 (+306607), chr16-438 (+322882), chr16-799 (+370750), 
chr16-723 (+374370) 
SOCS3 
chr17-826 (+16249), chr17-1223 (+22384), chr17-51 (+30513), chr17-525 (+35276), chr17-
1950 (+65135), chr17-2529 (+65997), chr17-2119 (+66730), chr17-2756 (+67237), chr17-
1827 (+74770), chr17-2118 (+75749) 
SP100 
chr2-2369 (-3570), chr2-1251 (+19), chr2-4992 (+2390), chr2-4993 (+23702), chr2-190 
(+41431), chr2-6135 (+162016), chr2-3944 (+173551), chr2-475 (+227527), chr2-1817 
(+227979), chr2-319 (+244660), chr2-1121 (+252511), chr2-4996 (+253022), chr2-4193 
(+262424), chr2-2680 (+284442) 
STAT1 
chr2-3280 (-100570), chr2-4931 (-37861), chr2-4508 (-24304), chr2-3911 (-6895), chr2-
1929 (+17051), chr2-841 (+43193), chr2-2932 (+52159), chr2-3279 (+66201), chr2-3910 
(+122614) 
STAT2 chr12-2875 (+1157) 
TRIM56 chr7-1633 (+14780), chr7-341 (+22883) 
TYK2 chr19-577 (+7643) 
USP18 chr22-9 (-35843), chr22-503 (-30016) 
XAF1 chr17-341 (-3177), chr17-774 (-2667), chr17-3083 (+40776) 
 
Supplementary Table 5: Specific genes and genomic region of peaks driving the 
associations of the ChIPseq dataset of SMAD1-bound loci from BMP4-treated U937 
cells with type I interferon associated pathways (see Supplementary Figure 3c). 
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GO BP: Regulation of type I IFN-mediated signalling pathway 
Genes Genomic regions of peaks 
HSP90AB1 chr6-102 (-21152), chr6-1128 (+399) 
IFNAR1 
chr21-140 (-75319), chr21-73 (-58374), chr21-141 (-19899), chr21-9 (+43342), chr21-199 
(+55174), chr21-28 (+61679) 
IFNAR2 
chr21-194 (-30994), chr21-72 (-17608), chr21-195 (-88), chr21-140 (+19664), chr21-73 
(+36609), chr21-141 (+75084) 
JAK1 chr1-336 (-55453), chr1-1948 (+73460), chr1-1947 (+81652), chr1-35 (+102205) 
MAVS chr20-323 (-7251), chr20-325 (-3104), chr20-259 (+31988) 
NLRC5 chr16-109 (+48152) 
PTPN1 
chr20-170 (-312648), chr20-6 (-217614), chr20-32 (-211571), chr20-428 (-191478), chr20-
222 (-162049), chr20-39 (-123715), chr20-223 (-122992), chr20-289 (-115560), chr20-224 
(-69308), chr20-116 (-54498), chr20-225 (+7615), chr20-290 (+31525), chr20-171 
(+48534), chr20-291 (+132192), chr20-431 (+156602), chr20-4 (+181096) 
PTPN11 chr12-355 (-4770), chr12-767 (+347) 
PTPN6 chr12-385 (+14306), chr12-274 (+18670) 
SOCS1 
chr16-162 (+407), chr16-105 (+22839), chr16-454 (+54144), chr16-161 (+95372), chr16-46 
(+150939), chr16-65 (+283229), chr16-17 (+283764), chr16-160 (+311713), chr16-21 
(+369046) 
SOCS3 
chr17-198 (+48), chr17-163 (+44103), chr17-16 (+87691), chr17-534 (+88138), chr17-80 
(+96677), chr17-79 (+101317), chr17-372 (+109018) 
STAT1 chr2-488 (-6284), chr2-847 (-32) 
STAT2 chr12-654 (+165) 
  
GO BP: type I IFN-mediated signalling pathway 
Genes Genomic regions of peaks 
ADAR chr1-647 (-21086), chr1-2080 (-8907), chr1-2079 (+321), chr1-1464 (+14668) 
EGR1 chr5-242 (-55) 
GBP2 chr1-1062 (+4245) 
HLA-A chr6-191 (+22541), chr6-270 (+25244) 
HLA-C chr6-730 (-123929), chr6-1032 (-15655) 
IFIT3 chr10-577 (+30635) 
IFITM3 chr11-568 (-35465) 
IFNAR1 
chr21-140 (-75319), chr21-73 (-58374), chr21-141 (-19899), chr21-9 (+43342), chr21-199 
(+55174), chr21-28 (+61679) 
IFNAR2 
chr21-194 (-30994), chr21-72 (-17608), chr21-195 (-88), chr21-140 (+19664), chr21-73 
(+36609), chr21-141 (+75084) 
IRF1 
chr5-508 (-216), chr5-717 (+22925), chr5-716 (+53074), chr5-191 (+63993), chr5-29 
(+67964) 
IRF2 chr4-124 (+22616) 
IRF4 chr6-246 (+213013), chr6-155 (+266736), chr6-885 (+272295) 
JAK1 chr1-336 (-55453), chr1-1948 (+73460), chr1-1947 (+81652), chr1-35 (+102205) 
PTPN1 
chr20-170 (-312648), chr20-6 (-217614), chr20-32 (-211571), chr20-428 (-191478), chr20-
222 (-162049), chr20-39 (-123715), chr20-223 (-122992), chr20-289 (-115560), chr20-224 
(-69308), chr20-116 (-54498), chr20-225 (+7615), chr20-290 (+31525), chr20-171 
(+48534), chr20-291 (+132192), chr20-431 (+156602), chr20-4 (+181096) 
PTPN11 chr12-355 (-4770), chr12-767 (+347) 
PTPN6 chr12-385 (+14306), chr12-274 (+18670) 
	 11	
SOCS1 
chr16-162 (+407), chr16-105 (+22839), chr16-454 (+54144), chr16-161 (+95372), chr16-46 
(+150939), chr16-65 (+283229), chr16-17 (+283764), chr16-160 (+311713), chr16-21 
(+369046) 
SOCS3 
chr17-198 (+48), chr17-163 (+44103), chr17-16 (+87691), chr17-534 (+88138), chr17-80 
(+96677), chr17-79 (+101317), chr17-372 (+109018) 
SP100 chr2-511 (-17177), chr2-91 (+243208) 
STAT1 chr2-488 (-6284), chr2-847 (-32) 
STAT2 chr12-654 (+165) 
XAF1 chr17-396 (-17078) 
  
GO BP: response to type I IFN 
Genes Genomic regions of peaks 
ADAR chr1-647 (-21086), chr1-2080 (-8907), chr1-2079 (+321), chr1-1464 (+14668) 
EGR1 chr5-242 (-55) 
GBP2 chr1-1062 (+4245) 
HLA-A chr6-191 (+22541), chr6-270 (+25244) 
HLA-C chr6-730 (-123929), chr6-1032 (-15655) 
IFIT3 chr10-577 (+30635) 
IFITM3 chr11-568 (-35465) 
IFNAR1 
chr21-140 (-75319), chr21-73 (-58374), chr21-141 (-19899), chr21-9 (+43342), chr21-199 
(+55174), chr21-28 (+61679) 
IFNAR2 
chr21-194 (-30994), chr21-72 (-17608), chr21-195 (-88), chr21-140 (+19664), chr21-73 
(+36609), chr21-141 (+75084) 
IRF1 
chr5-508 (-216), chr5-717 (+22925), chr5-716 (+53074), chr5-191 (+63993), chr5-29 
(+67964) 
IRF2 chr4-124 (+22616) 
IRF4 chr6-246 (+213013), chr6-155 (+266736), chr6-885 (+272295) 
JAK1 chr1-336 (-55453), chr1-1948 (+73460), chr1-1947 (+81652), chr1-35 (+102205) 
PTPN1 
chr20-170 (-312648), chr20-6 (-217614), chr20-32 (-211571), chr20-428 (-191478), chr20-
222 (-162049), chr20-39 (-123715), chr20-223 (-122992), chr20-289 (-115560), chr20-224 
(-69308), chr20-116 (-54498), chr20-225 (+7615), chr20-290 (+31525), chr20-171 
(+48534), chr20-291 (+132192), chr20-431 (+156602), chr20-4 (+181096) 
PTPN11 chr12-355 (-4770), chr12-767 (+347) 
PTPN6 chr12-385 (+14306), chr12-274 (+18670) 
SOCS1 
chr16-162 (+407), chr16-105 (+22839), chr16-454 (+54144), chr16-161 (+95372), chr16-46 
(+150939), chr16-65 (+283229), chr16-17 (+283764), chr16-160 (+311713), chr16-21 
(+369046) 
SOCS3 
chr17-198 (+48), chr17-163 (+44103), chr17-16 (+87691), chr17-534 (+88138), chr17-80 
(+96677), chr17-79 (+101317), chr17-372 (+109018) 
SP100 chr2-511 (-17177), chr2-91 (+243208) 
STAT1 chr2-488 (-6284), chr2-847 (-32) 
STAT2 chr12-654 (+165) 
XAF1 chr17-396 (-17078) 
	 	
Supplementary Table 6: Specific genes and genomic region of peaks driving the 
associations of the ChIPseq dataset of SMAD1-bound loci from BMP4-treated K562 
cells with Type I interferon associated pathways (see Supplementary Figure 3d).	
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Supplementary	Figure	1:	Reduced	upregula5on	of	hepcidin	in	response	to	BMP6	in	HCV	infected	cells	is	likely	via	TNFa	
induc5on	
a	Uninfected	or	HCV-infected	(MOI	=	0.02)	Huh7.5	cells	were	incubated	with	a	BtraBon	of	BMP9	overnight;	HAMP	mRNA	inducBon	in	response	
to	BMP9	was	not	suppressed	in	HCV-infected	cells		(two-tailed	Wilcoxon	matched	pairs	test;	p=0.2293;	n=3	biologically	independent	
experiments).	b	TNFA	mRNA	levels	increased	with	mulBplicity	of	infecBon	(n=3	biologically	independent	experiments;	plots	depict	mean	+/-	
SEM	expression	relaBve	to	the	endogenous	control	gene	GAPDH,	compared	to	untreated	cells).	c	HJV	mRNA	levels,	quanBﬁed	by	qRT-PCR	
relaBve	to	GAPDH	expression,	declined	in	HCV-infected	Huh7.5	cells	with	increasing	mulBpliciBes	of	infecBon	(MOI)	(n=3	biologically	
independent	experiments;	plots	depict	mean	+/-	SEM	expression	relaBve	to	GAPDH,	compared	to	uninfected	cells).	d	IncubaBon	of	Hep3B	cells	
with	exogenous	TNF	alpha	results	in	the	loss	of	HJV	mRNA	expression	(n=3	biologically	independent	experiments;	plots	depict	mean	+/-	SEM	
expression	relaBve	to	GAPDH,	compared	to	untreated	cells).	e	Pre-treatment	of	Hep3B	cells	with	20ng/mL	TNF-alpha	for	48h	reduced	their	
response	to	overnight	incubaBon	with	BMP6	(two-tailed	Wilcoxon	matched	pairs	test;	n=3	biologically	independent	experiments).		
f	Neutralizing	anB-TNF-alpha	anBbody	(Ab,	0.2	ug/mL)	over	the	course	of	a	10-day	HCV	infecBon	(MOI=0.02)	restored	BMP-mediated	hepcidin	
(HAMP)	inducBon.	Data	are	from	n=3	biologically	independent	experiments,	each	containing	a	BtraBon	of	5-6	BMP6	concentraBons	ranging	
from	0.22	–	18nM:	data	are	normalized	to	the	HAMP	expression	level	in	uninfected	(UI)	cells	given	the	equivalent	BMP6	dose;	graphs	depict	
mean	relaBve	expression	+/-	SEM;	Repeated	measures	one-way	ANOVA	with	Bonferroni’s	mulBple	comparison	test	adjusted	p-values	shown.	
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Supplementary Figure 2!
Supplementary	Figure	2:	BMP6	induces	a	transcriptome	reminiscent	of	Type	I	IFN	
signaling	
Pathway	analysis	of	microarray	from	Huh7.5	cells	treated	with	18nM	BMP6	for	24	
hours,	compared	to	vehicle	treated	cells	(n	=	2	independent	experiments,	each	run	in	
triplicate,	giving	a	total	of	6	RNA	extracts	per	condiBon).	The	top	20	‘pathway	maps’	
were	raised	by	MetaCore	sohware	analysis	of	the	transcriptome	of	BMP6	treated	
Huh7.5	cells.	The	blue	bar	highlights	the	BMP	signaling	pathway,	the	red	bar	
highlights	the	Type	I	IFN	signaling	pathway,	the	green	bar	highlights	development/
angiotensin	signaling	mediated	by	STAT,	all	are	signiﬁcant.	P-values	represent	results	
of	the	hypergeometric	test,	idenBcal	to	the	corresponding	one-tailed	version	of	
Fisher's	exact	test,	as	implemented	by	Metacore;	FDR	was	set	at	0.05.	
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Supplementary	Figure	3:	BMP6,	cell-cycle	progression	and	HCV	replica5on.		
a	Huh7	cells	were	incubated	with	BMP6	18	nM	for	24	h,	followed	by	qRT-PCR	analysis	of	HAMP,	
encoding	the	established	BMP-target	gene	hepcidin	and	CDKN1A	(encoding	p21)	mRNA	expression	
relaBve	to	the	endogenous	control	gene	GAPDH.	Plots	display	mean	±	SEM;	two-tailed	paired	t	tests	
based	on	n=3	biologically	independent	experiments	in	duplicate	wells.		
b	Huh7	cells	were	untreated	or	incubated	with	the	cytostaBc	agent	UCN-01	or	recombinant	human	
BMP6	for	48h,	followed	by	30	minutes	pulsed	incorporaBon	of	BrdU.	Cells	were	harvested	and	
immunostained	for	incorporated	BrdU	and	exposed	to	the	DNA-intercalaBng	dye	propidium	iodide.	
Percentages	of	cells	in	each	phase	of	the	cell	cycle	were	then	quanBﬁed	by	two-colour	ﬂow-cytometry.	
IncubaBon	with	BMP6	promotes	a	shih	in	phase	frequencies	akin	to	that	observed	with	the	cytostaBc	
drug	UCN-01,	characterized	by	a	staBsBcally-signiﬁcant	reducBon	in	the	percentage	of	cells	in	S-phase.	
Data	from	n=3	biologically	independent	experiments;	plots	depict	mean	+/-	SEM;	one-way	ANOVA	
within	each	phase	grouping:	Bonferroni’s	mulBple	comparison	test	adjusted	p-values	shown.		
c	OR6	cells	were	incubated	with	recombinant	human	IFNα-2a	or	UCN-01	and	assayed	at	72	h	post-
incubaBon	for	Renilla	luciferase	acBvity	(indicaBng	HCV	replicon	acBvity).	Data	from	n=3	biologically	
independent	experiments	conducted	in	triplicate	wells;	plots	depict	mean	+/-	SEM;	repeated	measures	
ANOVA:	Bonferroni’s	mulBple	comparison	test	adjusted	p-values	with	respect	to	untreated	cells	shown.	
UCN-01	does	not	directly	inhibit	the	Renilla	luciferase	reporter	enzyme	expressed	by	OR6	cells	(not	
shown).		
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Supplementary	Figure	4:	BMP6-regulated	IFN	pathway–related	genes	in	the	Type	I	IFN	
signaling	network	
a	Metacore	output	of	the	type	I	IFN	signaling	pathway	with	genes	upregulated	by	BMP6	
(IFNAR2,	JAK1,	STAT2,	IRF9,	ISG15,	IFI6)	indicated	by	red	‘thermometer’	symbol	and	
genes	downregulated	by	BMP6	(USP18,	PRMT1)	indicated	by	blue	‘thermometer’	signal.	
b	Clariﬁed	scheme	of	IFN	signaling	pathway	with	upregulated	by	BMP6	(IFNAR2,	JAK1,	
STAT2,	IRF9,	ISG15,	IFI6)	indicated	by	red	up	arrow	and	genes	downregulated	by	BMP6	
(USP18,	PRMT1)	indicated	by	blue	down	arrow.	
Supplementary Figure 5!
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Supplementary	Figure	5:	mRNA	expression	of	IFN-pathway	related	and	BMP-
pathway	related	genes	in	hepatocytes	treated	with	BMP6	
a	The	levels	of	IFNAR2,	JAK1,	STAT2,	IRF9,	ISG15,	IFI6,	HAMP	and	ID1	mRNA	in	
control	and	BMP6-treated	primary	human	hepatocytes.	Results	are	presented	as	
mean	±	SEM	(n=3	technical	replicates)	of	the	fold	change	compared	with	PBS-
treated	cells.	StaBsBcal	signiﬁcance	was	assessed	using	two-tailed	Student's	t	tests.	
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Supplementary	Figure	6:	Pathway	analysis	of	SMAD1-bound	loci	in	BMP4-treated	U937	cells	and	K562	cells		
GREAT	Gene	Set	Enrichment	Analysis	(GSEA)	for	SMAD1	peaks	derived	from	publicly	available	ChIPseq	datasets	for	U937	cells	
(a,	c)	and	K562	cells	(b,	d)	treated	with	BMP4.	Peaks	idenBﬁed	with	the	Homer	peak-calling	algorithm	were	subjected	to	GSEA	
with	the	GREAT	web-based	tool.	Pathways	deﬁned	as	signiﬁcant	by	region-based	binomial	analysis	with	reference	to	the	hg19	
GRCh37	genome	assembly	were	reported.	GSEA	results	from	interrogaBon	of	Gene	Ontology	(GO)	Molecular	FuncBon	(a,	b)	or	
Biological	Process	(c,	d)	databases	are	shown.	For	both	cell	types,	Molecular	FuncBon	databases	report	SMAD1-bound	loci	aher	
BMP4	treatment	were	enriched	in	genes	involved	in	TGF-beta	/	SMAD	type	signalling	as	expected	(indicated	by	black	boxes	in	a,	
b);	and	the	Biological	Processes	databases	report	SMAD1-bound	loci	aher	BMP4	treatment	were	enriched	in	genes	involved	in	
the	type	I	IFN	response	pathway	(black	boxes	in	c,	d).	Molecular	FuncBon	and	Biological	Processes	databases	diﬀer	in	their	
content	of	annotated	pathways.	
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Supplementary	Figure	6:	Pathway	analysis	of	SMAD1-bound	loci	in	BMP4-treated	U937	cells	and	K562	cells		
GREAT	Gene	Set	Enrichment	Analysis	(GSEA)	for	SMAD1	peaks	derived	from	publicly	available	ChIPseq	datasets	for	U937	cells	
(a,	c)	and	K562	cells	(b,	d)	treated	with	BMP4.	Peaks	idenBﬁed	with	the	Homer	peak-calling	algorithm	were	subjected	to	GSEA	
with	the	GREAT	web-based	tool.	Pathways	deﬁned	as	signiﬁcant	by	region-based	binomial	analysis	with	reference	to	the	hg19	
GRCh37	genome	assembly	were	reported.	GSEA	results	from	interrogaBon	of	Gene	Ontology	(GO)	Molecular	FuncBon	(a,	b)	or	
Biological	Process	(c,	d)	databases	are	shown.	For	both	cell	types,	Molecular	FuncBon	databases	report	SMAD1-bound	loci	aher	
BMP4	treatment	were	enriched	in	genes	involved	in	TGF-beta	/	SMAD	type	signalling	as	expected	(indicated	by	black	boxes	in	a,	
b);	and	the	Biological	Processes	databases	report	SMAD1-bound	loci	aher	BMP4	treatment	were	enriched	in	genes	involved	in	
the	type	I	IFN	response	pathway	(black	boxes	in	c,	d).	Molecular	FuncBon	and	Biological	Processes	databases	diﬀer	in	their	
content	of	annotated	pathways.	
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Supplementary	Figure	7:	EMSA	of	IRF1	binding	ISRE	and	SMAD4	binding	BRE	
Electromobility	shih	assay	of	(a,	b)	IRF1	protein	and	(c,	d)	SMAD4	protein	at	two-fold	
serial	diluBons	from	0.5	μM	incubated	with	0.5	nM	DNA	probe	of	25	bp	dsDNA	of	
interferon	sBmulated	response	element	(ISRE,	a,	c)	and	BMP	response	element	(BRE,	b,	
d)	at	37°C	for	10	minutes	before	returning	to	ice,	then	run	on	8%	(a,	b)	or	6%	(c,	d)	non-
denaturing	PAGE	at	100	V	for	3	h	at	4°C	in	0.5	x	TBE.	ISRE	+	1RF1	binding	(a)	and	SMAD4	
+	BRE	binding	(d)	are	indicated.	Experiments	were	repeated	twice	for	IRF1	and	three	
Bmes	with	SMAD4	with	similar	results.	
Supplementary Figure 8!
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Supplementary	Figure	8:	BMP6	enhances	expression	of	IRF2	and	IRF7,	and	the	IFN-alpha-mediated	upregula5on	of	IFN-
s5mulated	genes		
a	The	levels	of	IRF2	and	IRF7	mRNA	in	Huh7.5	cells	treated	with	2uM	dorsomorphin	(Dorso)	or	0.2uM	LDN-193189	(LDN)	30	
minutes	prior	to	co-incubaBon	with	18nM	BMP6	for	20h	(top	row)	or	1000U/mL	IFN-alpha	for	6h	(botom	row).	Plots	display	
mean	of	log-transformed	data	±	SD;	two-tailed	paired	t-tests	on	log-transformed	data	(n=3	independent	biological	replicates).			
b	MX1,	PLSCR1,	ISG16,	IFIT3,	and	IFITM1	mRNA	expression	in	Huh7.5	cells	treated	with	18nM	BMP6	followed	immediately	by	co-
incubaBon	with	a	BtraBon	of	IFN-alpha	(10-1000U/mL)	for	24h.	Data	from	3	biologically	independent	experiments	are	shown.	
Plots	indicate	means	±	SEM;	repeated	measures	ANOVA:	Bonferroni’s	mulBple	comparison	test	adjusted	p-values	are	indicated.	
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Supplementary	Figure	9:	SMAD1	and	IRF1	ChIP	peaks	in	similar	ac5ve	chroma5n	
regions	at	RSAD2,	SSBP3	and	ZC3HAV1	loci	
a-c	VisualisaBon	of	gene	loci	showing:	ChIP-seq	for	SMAD1	in	BMP4-treated	K562	cells,	
IRF1	in	IFNα-treated	K562	cells	and	SMAD1	in	BMP4-treated	CD34+	erythrocyte	
progenitors;	gene	structure,	in	accordance	with	RefSeq	annotaBon	(RefSeq/UCSC);	ChIP-
seq	for	histone	marks	H3K27ac,	H3K4Me1	and	H3K4Me3.	Boxes	denote	instances	of	IRF1	
and	SMAD1	peak	colocalisaBon	in	regions	of	acBve	chromaBn.	Loci	depicted	are	a	RSAD2	
(encoding	viperin)	+/-	10kb,	b	SSBP3	(encoding	single-stranded	DNA	binding	protein	3)	
+/-50kb,	and	c	ZC3HAV1	(encoding	zinc	ﬁnger	anBviral	protein-1)	+/-	20kb.		
d	mRNA	expression	of	RSAD2,	SSBP3	and	ZC3HAV1	was	upregulated	aher	incubaBon	of	
Huh7.5	cells	with	54nM	BMP6	for	72h.	Plots	display	mean	fold	change	relaBve	to	
untreated	cells	±	SEM;	one-tailed	paired	t-tests	(n=3	independent	biological	replicates).	
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Supplementary Figure 10 (legend overleaf)!
Supplementary	Figure	10:	Gene	expression	in	HCV-infected	Huh7.5	cells	treated	with	
BMP6	
HCV	infected	Huh7.5	cells	were	incubated	with	a	BtraBon	of	BMP6	(2-52nM)	for	5	days	
and	then	assayed	for	expression	of	
a	the	BMP6	target	genes	Hepcidin,	ID1,	and	SMAD7	
b	ﬁve	genes	in	the	IFN	signaling	pathway	(IFNAR2,	JAK1,	STAT2,	IRF1,	IRF9)	
c	the	IFN	pathway	inhibitor	USP18		
Data	summarise	four	biologically	independent	experiments.	P-values	report	the	results	
of	Friedman	tests	(non-parametric	repeated	measures	ANOVA)	based	on	treatments	0,	
2,	6	and	18nM	BMP6	(52nM	precluded	owing	to	missing	data	from	one	of	the	four	
biological	replicates);	if	not	shown,	Friedman	test	p-value	>0.05;	*	or	**	represents	
signiﬁcance	of	speciﬁc	comparisons	with	adjusted	p-value	<0.05	or	<0.01	based	on	
Dunn's	mulBple	comparison	post-test.	
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Supplementary Figure 11 (legend overleaf)!
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Supplementary	Figure	11:	Eﬀect	of	BMP	pathway	inhibi5on,	Bx795,	BMPs	and	
Ac5vins	on	HCV	replica5on	
a	Leh	-	Luciferase	acBvity	in	OR6	cells	treated	with	2uM	dorsomorphin,	0.2uM	
LDN-193189	or	vehicle	control	(water)	for	30	minutes	prior	to	co-incubaBon	with	
1000U/mL	IFN-alpha	for	24h	(two	tailed	paired	t-test;	n=3	biologically	independent	
experiments;	plots	depict	mean	+/-	SEM);	Right	-	Luciferase	acBvity	in	OR6	cells	treated	
with	100nM	LDN-193189	or	vehicle	control	(water)	for	30	minutes	prior	to	co-
incubaBon	with	18nM	BMP6	or	a	BtraBon	of	IFN-alpha	(40,	60	80U/mL)	for	72h.	Data	
from	n=3	experiments	containing	3-5	replicates	(fewer	replicate	experiments	for	IFNa	
40	and	60U/mL	were	available);	plots	depict	mean	+/-	SEM;	one-way	ANOVA:	
Bonferroni’s	mulBple	comparison	test	adjusted	p-values	compared	to	untreated	are	
indicated,	except	where	otherwise	marked.	
b	OR6	cells	were	exposed	to	BMP6	or	IFN	in	the	presence	of	increasing	doses	of	Bx795	
(TBK1	/	IKKepsilon	inhibitor)	or	its	vehicle	DMSO.	Data	from	n=3	biologically	
independent	experiments;	plots	depict	mean	+/-	SEM;	2-way	ANOVA:	Bonferroni’s	
mulBple	comparison	test	adjusted	p-values	are	indicated.	
c	Leh	-	Timecourse	of	luciferase	acBvity	in	OR6	cells	treated	with	3nM	BMP9	for	24,	48,	
72h	(two-tailed	paired	t	test	at	each	Bmepoint	compared	to	untreated,	n=3	biologically	
independent	experiments;	plots	depict	means	+/-	SEM);	Right	-	Luciferase	acBvity	in	
OR6	cells	treated	for	24	hours	with	IFN-alpha,	BMP6	or	a	BtraBon	of	BMP4.	Data	from	
n=2	biologically	independent	experiments	performed	in	duplicate;	plots	depict	mean	
an	+/-	SEM;	one-way	ANOVA:	Bonferroni’s	mulBple	comparison	test	adjusted	p-values	
compared	to	untreated	are	indicated.	
d	Leh	-	Luciferase	acBvity	in	OR6	cells	treated	with	AcBvin	A,	GDF1,	or	BMP15,	for	24	
hours;	data	from	n=3	biologically	independent	experiments,	each	performed	in	
triplicate.	Plots	indicate	means	±	SEM;	repeated	measures	ANOVA:	Bonferroni’s	
mulBple	comparison	test	adjusted	p-values,	comparing	to	untreated,	are	indicated.	
Right	-	Luciferase	acBvity	in	OR6	cells	treated	with	IFN-alpha,	BMP6,	or	GDF15;	data	
from	n=2	biologically	independent	experiments;	p-values	represent	result	of	two-tailed	
unpaired	t-tests,	comparing	to	untreated.	
e	Luciferase	acBvity	72h	post-addiBon	in	OR6	cells	treated	with	0.1uM	LDN-193189	for	
30	minutes	prior	to	addiBon	of	18nM	BMP6	or	a	dose	BtraBon	of	AcBvin	B	or	AcBvin	A.	
Data	from	n=3	biologically	independent	experiments	comprising	mulBple	replicates	
(2.0nM	AcBvin	A	/	AcBvin	B	was	included	in	n=1	experiment);	plots	depict	means	+/-	
SEM;	two-way	ANOVA	with	Bonferroni’s	mulBple	comparisons	test	conducted	
between	respecBve	+/-	LDN-193189	condiBons.	
Supplementary Figure 12!
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Supplementary	Figure	12.	Model	of	how	BMP/SMAD	signaling	interacts	with	an5viral	
immunity	and	HCV	infec5on.	IFN	acBvity	and	HCV	infecBon	are	known	to	be	mutually	
antagonisBc;	BMP/SMAD	signaling	is	known	to	control	iron	homeostasis	through	
regulaBng	hepcidin.	Our	data	show	that	BMP/SMAD	signaling	alters	the	expression	of	a	
gene	repertoire	(including	downregulaBng	USP18)	leading	to	an	enhancement	of	IFN	
acBvity,	and	has	IFN-independent	anBviral	acBvity	that	suppresses	HCV	replicaBon.	
Conversely,	HCV	inhibits	BMP/SMAD	signaling,	suppressing	hepcidin	thereby	
predisposing	to	hepaBc	iron	accumulaBon.		
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Supplementary	Figure	13.	Uncropped	Western	Blots.		Full	blots	corresponding	to	the	
data	shown	in	Figures	3b	and	4c.		Dashed	lines	indicate	regions	of	blots	shown	in	main	
ﬁgures.	Molecular	weight	markers	in	kDa	are	indicated;	LDN	=	LDN-193189.	
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